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ABSTRACT 
Breast cancer is unanimously considered a highly heterogeneous disease due to its diverse 
molecular features. Breast tumor kinase (BRK), also known as protein tyrosine kinase 6 
(PTK6), is a non-receptor tyrosine kinase that is highly expressed in over 80% of breast 
carcinomas. The role and mechanism of action of enzymatically activated BRK in breast 
pathology are unclear. The objectives of this project were to reveal the effect of BRK activation 
on cell migration, proliferation and tumorigenesis. We also aimed to determine the mechanism 
of action of BRK in the promotion of cell proliferation. We used BRK-negative cells 
(MCF10A, MDA-MB-231 and HEK293) to generate three sets of stable cell lines that stably 
expressed GFP alone, GFP-BRK-WT or GFP-BRK-Y447F (constitutively active) by retroviral 
infections. We also stably knocked down BRK from BRK-positive cells BT20 and SKBR3 by 
RNA interference using shRNAs against BRK. Western blotting, immunoprecipitation and 
qPCR studies were conducted to evaluate protein expression, protein-protein interaction and 
mRNA expression, respectively. Both sets of cell lines were used to determine the effect of 
BRK on cell proliferation (automated cell counter), cell migration (transwell and wound healing 
assay), transformation (colony formation assay) and tumor formation (mouse Xenograft assay). 
To investigate the mechanism of action of BRK, we validated downstream of tyrosine kinases 1 
(Dok1), a tumor suppressor, as a BRK substrate. Deletion or site-directed mutagenesis was 
performed to map BRK-targeted tyrosines in Dok1 protein. Results obtained from this research 
project showed that stable expression of the constitutively active mutant of BRK (BRK-Y447F) 
in MDA-MB-231 cells led to a significant increase in the cell proliferation, migration rate and 
promoted colony formation and drastically enhanced tumor formation in athymic nude mice in 
comparison to control cells. Additionally, depletion of BRK abrogated the migration of BT20 
and SKBR3 cells. Furthermore, we showed that BRK interacts with and phosphorylates Dok1, 
inducing Dok1 downregulation via a ubiquitin-proteasome-mediated mechanism. Together, our 
results show that the activation of BRK is essential for mammary gland tumorigenesis and 
suggest that targeting of Dok1 for degradation is a novel mechanism of action of BRK in the 
promotion of cell proliferation, migration and tumor formation. 
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1. Introduction 
1.1 Impact of breast cancer 
In both the developed and the developing world, breast cancer is the most commonly 
diagnosed female malignancy and one of the leading causes of cancer related death in women. It 
was predicted that every year over 1.5 million women will be diagnosed with breast cancer, 
accounting for approximately 23 % of all cancers and ultimately taking over half a million lives 
per year worldwide (Ginsburg and Love, 2011). The global economic impact of breast cancer is 
staggering, which is estimated at $88 billion in 2008 (American Cancer Society-2008). Statistics 
Canada projects more than 24,400 new cases of breast cancer diagnoses and over 5000 deaths of 
Canadian women each year. One in nine women will be diagnosed with breast cancer and 1 in 30 
will die of this terrible disease in their lifetime (Canadian Cancer Statistics 2014).  
 
1.1.1 Breast cancer and molecular classifications 
Breast cancer is a highly heterogeneous group of cancers, with diversity in its 
morphology, molecular genetics, biology, and clinical outcome. Adenocarcinoma is a cancer of 
the epithelium that originates in glandular tissue and most breast cancers start as 
adenocarcinoma. Adenocarcinoma progresses into ductal carcinoma in situ (DCIS), also arising 
from the ductal epithelium, or lobular carcinoma in situ (LCIS), which originates from the 
epithelium of the lobules. The most common kind of breast cancer, invasive ductal carcinoma 
(IDC) also called infiltrating ductal carcinoma and infiltrating lobular carcinoma (ILC), grows 
from DCIS and LCIS respectively (Sharma et al., 2010). The invasive tumor cells metastasize 
preferentially to the bone and the lungs (Figure 1.1).  
 The biology of breast tumors remains poorly understood, although, several measures 
have been undertaken to distinguish tumor features according to tumor grade, stage and gene 
profile. Grading is based on the microscopic structure of the tumor and scaled from 1-3, from the 
least aggressive in appearance to the most aggressive. The stages are classified from noninvasive 
Stage 0 to the highly metastatic Stage IV, based on measurement of the tumor, lymph node 
involvement, and the metastatic spread (Perou et al., 2000; Sorlie et al., 2001; Sotiriou et al., 
2003).  
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Figure 1.1: Progression of human breast cancer. Normal epithelium of glandular tissues alters 
into malignant adenocarcinomas, then becomes tumorigenic (carcinoma in situ) and 
subsequently develops into invasive carcinomas. Malignant tumor cells metastasize to the bone 
and the lungs.(Adapted from Siegel and Massague, 2003). 
 
Six molecular classes of breast cancer have also been defined through gene expression profiling 
(Andre and Pusztai, 2006; Sorlie et al., 2001) (Table 1). They include: 1. Normal breast-like, 2. 
Basal-like (Triple-negative), 3. Luminal A, 4. Luminal B, 5. Human epidermal growth factor 
receptor 2 (HER2)-positive, and 6. Claudin-low. 
The luminal subtypes that make up hormone receptor expressing breast cancer represent 
67% of the tumors and express luminal cytokeratins 8/18, estrogen recptors (ER) and genes 
associated with ER activation such as LIV1 and Cyclin D1. The basal-like tumors are usually 
ER-, PR- and HER2-negative and are also associated with germ-line BRCA1 mutations, one of 
the most important forms of the hereditary breast cancer (Andre and Pusztai, 2006; Foulkes et 
al., 2003).  
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Table 1:  Molecular subtypes of breast cancer. This table shows the gene expression pattern of 
each molecular class of breast cancers including histological grade and metastatic potential 
(Munirah et al., 2011; Sabatier et al., 2014; Taube et al., 2010). ER (estrogen receptor); PR 
(progesterone receptor); GRB7 (Growth factor receptor- bound protein7) and BRCA1 (Breast 
Cancer 1) 
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HER+   
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Histological 
high grade  
and highly 
metastatic    
 
Histological 
low grade     
and less 
metastatic 
 
 
Histological 
low grade     
and less 
metastatic 
 
 
Histological 
high grade      
and very 
aggressive 
 
 
High 
metastatic 
potential 
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HER2-positive breast cancers are characterized by high expression of HER2 usually as a result 
of amplification of 17q12q21 locus that contains the HER2 gene. Unlike other breast tumors, 
basal-like and HER2 tumors have a higher proportion (40-80%) of TP53 mutations (Andre and 
Pusztai, 2006). The normal breast-like subtype has expression patterns similar to nonmalignant 
tissue. Luminal A tumors have the longest survival times, luminal B tumors have intermediate 
survival times, whereas the basal-like and HER2 positive subtypes display the shortest survival 
times. Luminal A and B subtypes possess low and intermediate metastatic properties 
respectively, while the basal-like and HER2 positive subtypes are highly aggressive (Sorlie et al., 
2003) tumors that express low levels of the tight junction claudin 3, as well as E-cadherin. They 
are equally characterized by a low expression of luminal markers and a high expression of 
mesenchymal markers and are associated with poor prognosis. Claudin-low tumors are more 
enriched in epithelial-to-mesenchymal transition (EMT) and tumor initiating cell features, 
immune system responses and stem cell-associated biological processes (Prat et al., 2012). 
Despite tremendous progress in cancer research, the heterogeneous nature of breast 
cancer is limiting the design of effective therapies. Breast cancer treatment typically includes 
surgical excision of the tumor mass in combination with chemotherapy and/or radiation therapy 
(Horgan et al., 2012). However, these conventional therapies are often ineffective due to several 
reasons such as treatment target inaccuracy, recurrence of the tumor and in some cases primary 
or acquired resistance to conventional therapies (Bonavida and Kaufhold, 2015). In order to 
overcome these common challenges in breast cancer treatment, the major focus of research today 
is to identify and characterize potential molecules that play a significant role in pathogenesis, 
progression and resurgence of cancer. Targeting these potential markers will potentially pave a 
new window in breast cancer treatment. Examples of successful targeted therapies include 
Tamoxifen, an antagonist of the ER that blocks the effects of estrogen (Jordan, 2014), and 
Trastuzumab (Herceptin), a monoclonal antibody that inhibits the activity of HER2 (Roskoski, 
2014). Overexpression, gene amplification, or mutations of other tyrosine kinases have a strong 
association with carcinogenesis (Foth et al., 2014; Ko et al., 2014; Morel et al., 2014; Peng et 
al., 2014b), thus making them promising therapeutic targets. The goal of my Ph.D. project was to 
investigate the role of a non-receptor tyrosine kinase, breast tumor kinase (BRK), which is 
overexpressed in approximately 80% of breast tumors. 
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1.2 Protein kinases 
 
A large family of enzymes known as kinases catalyzes protein phosphorylation. Kinases 
transfer the γ-phosphate group of ATP onto a selective residue (such as Ser, Thr or Tyr) of a 
target protein substrate (Hunter, 2014). Phosphorylation plays a major role in protein functioning 
and can turn enzymes on and off. For example, phosphorylation of Tyrosine 416 and 527 turns 
Src kinase on and off, respectively (Guarino, 2010). Phosphorylation thus is an indispensable 
part of cellular processes. 
Approximately 2% of the eukaryotic genome encode protein kinases, which make them 
one of the largest and most influential gene families (Manning, 2005). There are 518 protein 
kinases in the human genome (Manning et al., 2002) of which 90 are classified as protein 
tyrosine kinases (Figure 1.2). A protein tyrosine kinase transfers the phosphate group specific to 
the tyrosine on the target protein. Based on sequence similarity and divergent genetic structural 
organization similarities, tyrosine kinases have been further separated into either receptor or non-
receptor tyrosine kinase families. The receptor tyrosine kinase family has 58 members which are 
divided into 20 subfamilies (Figure 1.3), whereas non-receptor tyrosine kinase family is 
comprised of 32 members which are divided into 10 subfamilies (Figure 1.4) (Robinson et al., 
2000). 
Tyrosine kinases play a major role in various biochemical pathways and it has been 
reported that up to 30% of the proteome can potentially be phosphorylated by protein kinases 
(Manning, 2005). In fact, they participate in multiple cellular functions including cell growth, 
differentiation, cell motility, metabolism, survival as well as apoptosis. Hence, any deregulation 
of the phosphorylation process may alter cell function and result in a disease state (Rauch et al., 
2011). Therefore, protein kinases have emerged as major targets of drug discovery. In fact, 
approximately one-third of the contemporary validated drugs used to treat cancer are based on 
kinase inhibition in the pharmaceutical armoury (Pearl and Barford, 2002; Sun et al., 2015). 
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Figure 1.2: Phylogram of the human protein tyrosine kinase family A. Receptor tyrosine kinases. 
B. Non-receptor tyrosine kinase family. These kinase family trees are generated based on amino 
acid sequence identity and constructed by the EBI clustalw and numbers on each node dictate the 
evolutionary distance of most recent common ancestor in years (million).  
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Figure 1.3: Class and domain organization of human receptor RTKs are shown schematically. The 
cytoplasmic part of the receptor is on the bottom and top is the extracellular portion of the 
receptors (Hubbard and Till, 2000; Robinson et al., 2000). 
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Figure 1.4. Class and domain topology of non-receptor RTKs are shown schematically. The 
boxes indicating SH3, SH2 and Kinase domain are defined by different colors as indicated in the 
figure. Family members are involved in tumor progression or suppression is also shown in 
figure. (Goel and Lukong, 2015; Chakraborty et al., 2006; Cohen et al., 2010; Coopman and 
Mueller, 2006; Di Stefano et al., 2007; Gil-Henn et al., 2013; Golubovskaya et al., 2009; Hoare 
et al., 2008; Hornakova et al., 2011; Hussain et al., 2011; Ivanova et al., 2013; Mahajan and 
Mahajan, 2010; Marotta et al., 2011; Miah et al., 2012; Montero et al., 2011; Sang et al., 2012; 
Tabaries et al., 2015; Wendt et al., 2013; Yadav and Denning, 2011; Ye et al., 2013a; Ye et al., 
2013b; Zhao et al., 2010; Zhu et al., 2008). 
 
1.3 BRK family kinases (BFKs) 
Based on exon-intron boundary organization, BRK family kinases (BFKs) are comprised 
of three members namely BRK or protein tyrosine kinase 6 (PTK6), Fyn related kinase (FRK) or 
protein tyrosine kinase 5 (PTK5), and Src-Related tyrosine kinases lacking C-terminal 
Regulatory tyrosine and N-terminal Myristoylation Sites (SRMS) or protein tyrosine kinase 70 
(PTK70) (Goel and Lukong, 2015). The BFKs have 8 exons and this unique exon-intron pattern 
of BFKs is evolutionary distinct from Src family kinases (SFKs), which have 12 exons (Serfas 
and Tyner, 2003). 
BRK is a non-receptor tyrosine kinase also known as PTK6, murine ortholog, Sik (Src-
related intestinal kinase) was cloned in three separate studies in the early 1990s. BRK was first 
identified in a screen for protein tyrosine kinases in human melanocytes (Lee et al., 1993), 
followed by a study screening for novel kinases in metastatic breast cancers (Mitchell et al., 1994), 
and lastly in an experiment assessing epithelial cell differentiation in the mouse small intestine 
(Siyanova et al., 1994). The human PTK6 gene was mapped to chromosome 20q13.3. The gene 
is 10 kb long and is comprised of 8 exons that code for the BRK protein, consisting of 451 amino 
acid residues. In addition, a BRK isoform produced by alternative splicing has been identified, 
which encodes a 15 kDa protein called ALT-PTK6 (Brauer et al., 2011), initially termed λm5, 
and is composed of 134 amino acids (Mitchell et al., 1997).  
FRK also known as PTK5, Rak, Bsk, Iyk and Gtk, was cloned by several research 
laboratories in the early 1990s. FRK was first cloned from a human hepatoma cell line (Lee et 
al., 1994) as well as from human breast cancer cells (Cance et al., 1994). The murine homolog of 
FRK, Bsk, was cloned from the kidney and islets of Langerhans of the mouse (Oberg-Welsh and 
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Welsh, 1995). The human FRK localizes to chromosome 6q22.1, and the gene encodes a protein 
of 58 kDa, composed of 505 amino acids (Lee et al., 1994). An alternative transcript variant of 
FRK has also been identified in transcriptome studies of the entire human cDNAs library (Ota et 
al., 2004).  
SRMS is the 3
rd
 member of the BRK family. It was cloned from mouse embryonic 
neuroepithelial cells (Kohmura et al., 1994). The human orthologue of SRMS maps on 
chromosome 20q13.33 and is composed of 8 exons which encode a protein of 54 kDa, composed 
of 488 amino acids (Deloukas et al., 2001). 
The BFKs are structurally homologous with Src tyrosine kinase and composed of Src 
homology domains 3 and 2 (SH3 and SH2), and a kinase domain. Both BRK and FRK have a 
putative C-terminal regulatory tyrosine and display a similar architecture to Src kinases, 
however, SRMS is lacking a C-terminal tail (Serfas and Tyner, 2003) (Figure 1.5). Unlike Src 
family kinases, the human BFKs lack the myristoylated N-terminal consensus sequence required 
for membrane anchorage. Conversely, rodent FRK has a glycine residue at position 2, which 
allows it to myristoylate and localizes to the cell membrane (Sunitha and Avigan, 1996). BRK 
preferentially localizes to the cytoplasm but some is found in the nucleus (Miah et al., 2014; 
Serfas and Tyner, 2003). SRMS was shown to have a punctate cytoplasmic localization (Goel et 
al., 2013). However, FRK has a putative nuclear localization signal (NLS) motif 
(KRxxxxxFFxxRRR) in the SH2 domain that contains two groups of basic amino acids separated 
by spacer amino acids that dictates its nuclear localization in COS7 Monkey kidney cells (Serfas 
and Tyner, 2003), although other studies have indicated that FRK localizes to specific structures 
in the cytoplasm (Sunitha and Avigan, 1996).  
Functional redundancy of the PTKs is common, since these enzymes tend to share their 
substrates (Carreno et al., 2002; Xian and Zhou, 2004). For example, Docking protein 1 is a 
substrate of both BRK (Miah et al., 2014) and Src (Niu et al., 2006). Homozygous deletion of 
BRK, FRK and SRMS in mice did not show any detectable phenotypic effect, perhaps due to 
functional redundancy. More specifically, BRK or SRMS deficient mice were viable and fertile, 
and depletion of FRK did not demonstrate any developmental abnormalities (Kohmura et al., 
1994); (Chandrasekharan et al., 2002; Haegebarth et al., 2006). However, overexpression of 
PTKs is associated with different human malignancies including cancer (Shchemelinin et al., 
2006). FRK has been shown to be a potential inhibitor of tumor progression. Overexpression of 
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FRK in breast ductal carcinoma cells arrests the cells in G1 phase of the cell cycle, hindering 
their proliferation (Meyer et al., 2003), while the depletion of FRK promotes epithelial cell 
transformation to mesenchymal cells (Yim et al., 2009). Likewise, in glioma cells, both mRNA 
and protein levels of FRK are significantly repressed suggesting a tumor suppressive function of 
FRK (Shi et al., 2015; Zhou et al., 2012). Conversely, it has recently been reported that SRMS 
levels increase with breast tumor grades (Goel et al., 2013).  
 
 
Figure 1.5.  Schematic structure of BRK, FRK and SRMS tyrosine kinases. They share structural 
similarity, including the SH3 and SH2 that regulate protein-protein interaction and a conserved 
catalytic domain. BRK, FRK and SRMS are activated by phosphorylation of Y342, Y387 and 
Y380, and inactivated by K219M, K262M and K258M mutations, respectively. The tyrosine at 
447 in BRK and at 497 in FRK regulates kinase activity. In contrast to BRK and FRK, SRMS 
lacks a C-terminal regulatory tail. 
 
Although BRK deficient mice are viable and fertile, overexpression of BRK has been 
detected in many breast cancer cell lines, primary mammary gland tumors, and is typically 
undetected in normal mammary glands or benign tumors (Barker et al., 1997; Ludyga et al., 
2011). However, it has been recently reported that BRK is also expressed in the mammary 
glands of healthy individuals, but it becomes enzymatically active only in the malignant form of 
mammary tumors (Peng et al., 2014a). 
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1.4 BRK structure, activity and regulation 
BRK has the Src homology (SH) domains SH3, SH2, a kinase domain and a putative C-terminal 
regulatory tyrosine. It also displays a similar architecture and has 30–45% sequence identity with 
Src kinases (Serfas and Tyner, 2003). However, it lacks the amino-terminal myristoylation signal 
that localizes Src to the cell membrane, and therefore, it is not specifically targeted to the 
membrane (Figure 1.6) (Vasioukhin et al., 1995). Hence, its intracellular localization is flexible 
and it therefore localizes in the nucleus and cytoplasm, as well as at the cell membrane 
(Haegebarth et al., 2004). The SH3 domain binds to proline-rich regions of the consensus PXXP 
in substrate proteins. This domain is involved in intramolecular interactions that regulate kinase 
activity, interactions with substrates, cellular localization, and associated with other protein 
targets (Pawson, 1995). The SH2 domain recognizes and binds to phosphorylated tyrosine 
residues, with the specificity being determined by the 3-5 amino acids following the tyrosine 
residue (the peptide motifs for Src-SH2 was (H)(Y/M/F/H)pY(T/A/N)(M/Q/V/I)(I/M) and for 
BRK was (H/E/N/D)(M/Y/H/F)pY(D/E)(I/N/V/M)(C/V/Y)) (Songyang et al., 1993; Zhao et al., 
2013a).
 
Figure 1.6.  Schematic structure of BRK and Src tyrosine kinases. BRK and Src share 44% 
amino acid identity. These include the SH3 and SH2 that regulate protein-protein interaction and 
a conserved catalytic domain. BRK and Src are activated by phosphorylation of Y342 and Y419, 
and inactivated by K219M and K295M mutations, respectively. The tyrosine at 447 in BRK and 
at 527 in Src regulates kinase activity. In contrast to Src, BRK lacks an N-terminal consensus 
myristoylation site. 
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The SH3 and SH2 domains of BRK like Src family members are involved in 
intramolecular interactions with the kinase domain to form an autoinhibited conformation (Qiu 
and Miller, 2002). Similar to Src kinases, BRK is regulated negatively by phosphorylation of C-
terminal tyrosine 447 (which is analogous to the regulatory Y530 of Src) (Figure 5). However, it 
remains to be ascertained how this tyrosine becomes phosphorylated in BRK. It is known that it 
is neither phosphorylated by itself, nor by Csk (Qiu and Miller, 2002) which plays this role in 
Src-family PTKs (Liu et al., 1993). It is deduced that phosphorylation of BRK on Tyr-447 
induces the intramolecular interaction of this residue with the SH2 domain of the protein. This 
subsequently induces the binding of the SH3 domain to the linker region connecting the SH2 
domain and the kinase domain, which comprises the series of events that constitutively prevent 
the binding of ATP to the critical catalytic residues rendering BRK inactive. Mutation of tyrosine 
447 to phenylalanine significantly enhances the kinase activity of BRK (Derry et al., 2000; 
Lukong and Richard, 2003; Qiu and Miller, 2002; Miah et al., 2012), suggesting an inhibitory 
role for this residue. 
The biochemical and molecular analysis has revealed that BRK is capable of 
autophosphorylation at tyrosine 342 which is located in the kinase domain (Qiu and Miller, 
2002). It is also observed that this tyrosine residue is located in the activation loop of the active 
site of the catalytic domain and is conserved through evolution in different members of PTKs. 
Autophosphorylation of this conserved tyrosine results in conformational alterations within the 
activation loop, which results in full activation of the enzyme (Lin et al., 2003). 
 
1.5 BRK interacting partners, substrates and biology 
Although the biological role of BRK remains largely unknown, progress has been made 
in identifying the endogenous physiological substrates of BRK in the normal cells as well as in 
various cancers. Xian et al. reported that BRK is co-amplified and co-overexpressed with HER2 
in human breast cancer (Xiang et al., 2008). Consistent with its potential role in tumorigenesis, 
BRK has been found in complexes with proteins such as epidermal growth factor receptor 
(EGFR) (Kamalati et al., 1996), the putative adaptor protein BKs (Mitchell et al., 2000), GTPase 
activating protein-associated p65 (Vasioukhin and Tyner, 1997) , RNA binding proteins (e.g. 
Sam68, SLM-1 and SLM2) (Derry et al., 2000; Haegebarth et al., 2004), the EGFR family 
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member  HER3 (Kamalati et al., 2000), and the focal adhesion protein paxillin (Chen et al., 
2004), the serine-threonine kinase PKB/Akt (Zhang et al., 2005). It has also been shown to 
enhance the mitogenic signals of EGF (Brauer and Tyner, 2010; Hussain and Harvey, 2014; 
Kamalati et al., 2000). Thus, BRK may also directly or indirectly regulate the downstream 
signaling molecules in the EGFR pathway. 
Knockdown of BRK in breast carcinoma cells can significantly suppress proliferation 
(Harvey and Crompton, 2003). It is also possible that BRK can mediate cell proliferation by 
potentially functioning as an adaptor protein via a kinase-independent mechanism (Harvey and 
Crompton, 2003). It has been reported that BRK directly interacts with Akt, which results in the 
inhibition of Akt kinase activity and downstream signaling in unstimulated cells (Zhang et al., 
2005). However, upon EGF stimulation the BRK-Akt complex dissociates, resulting in activation 
of Akt signaling (Serfas and Tyner, 2003). Taking all the aforementioned information into 
account, it can be assumed that the biological function of BRK mostly depends on growth factor 
receptor inputs that mediate multiple intracellular signaling pathways.  
The first identified BRK substrate was RNA-binding protein Sam68 (Src associated 
during mitosis, 68 kDa) (Derry et al., 2000). Lukong et al. showed that Sam68 is phosphorylated 
upon EGF stimulation in a BRK-dependent manner in breast cancer cells (Lukong et al., 2005; 
Lukong and Richard, 2003). Although Sam68 can be phosphorylated by several intracellular 
tyrosine kinases, BRK phosphorylates and sequesters Sam68 in the nucleus, resulting in negative 
regulation of the RNA binding function of Sam68 (Derry et al., 2000). BRK substrates also link 
BRK to several signal transduction pathways as shown in Figure 1.7. They include the serine-
threonine kinase Akt (Zhang et al., 2005), insulin receptor substrate-4 (IRS-4) (Qiu et al., 2005), 
signal transducer and activator of transcription 3 (STAT3) (Liu et al., 2006), STAT5b (Weaver 
and Silva, 2007), p190 (Shen et al., 2008), kinesin-associated protein 3A (Lukong et al., 2008), 
polypyrimidine tract-binding (PTB) protein-associated splicing factor (PSF) (Lukong et al., 
2009), and β-catenin (Palka-Hamblin et al., 2010). STAT3, for instance, is phosphorylated and 
specifically activated by BRK, resulting in increased cell proliferation (Liu et al., 2006), while 
phosphorylation of Tyr 1105 in p190 enhanced its association with p120RasGAP, leading to Rho 
inhibition and Ras activation, which results in turn in cell migration (Bradley et al., 2006; 
Ostrander et al., 2010). Overall, the identified and validated substrates of BRK are associated 
with the mitogenic and cell migration pathways. 
 16 
 
Tyrosine phosphorylation sites have been identified for a number of BRK substrates. 
Paxillin has been identified as a binding partner and a substrate of BRK, being phosphorylated at 
Y31 and Y118 upon EGF stimulation. Phosphorylation at these two positions creates a binding 
site for Crk11, leading to small GTPase Rac1 activation (Chen et al., 2004). Through this action, 
BRK promotes cell motility and invasion and acts as a mediator of EGF-induced migration and 
invasion (Chen et al., 2004).   
 
Figure 1.7. BRK acts as mediator of multiple signaling pathways. BRK signaling is downstream 
of EGF receptors and stimulates multiple signaling pathways which control several cellular 
processes, including cell migration, proliferation and survival. Other receptors like IGF-1R can 
activate BRK, resulting in the phosphorylation of substrates such as Dok1, IRS-4, KAP3A, PSF, 
β-catenin, SLM1 and SLM2 or other unidentified substrates. 
 
BRK-induced phosphorylation of STAT5b was mapped to Y699 that is essential for 
transcriptional activation and suggesting that BRK signals downstream to STAT5b to mediate 
proliferation of breast cancer cells (Weaver and Silva, 2007). In addition, Lukong et al. showed 
 17 
 
that KAP3A is required by BRK to promote cell migration, and BRK-induced phosphorylation 
of PSF leads to cell cycle arrest (Lukong et al., 2008; Lukong et al., 2009). Moreover, in human 
breast cancer, BRK becomes activated by the stimulation of insulin-like growth factor-1 receptor 
(IGF-1R) (Qiu et al., 2005) (Figure 1.7). However, BRK is associated with nuclear and 
cytoplasmic β-catenin and inhibits β-catenin-regulated transcription in colorectal cancer (Palka-
Hamblin et al., 2010). In a recent proteomic study, a tumor suppressor, downstream of tyrosine 
kinase 1 (Dok1), was identified as a potential substrate of BRK (Takeda et al., 2010). In 
addition, my studies in this thesis have demonstrated that BRK interacts with and phosphorylates 
Dok1 and to promote cell proliferation and migration  
 
1.6 Downstream of tyrosine kinase 1 (DOK1) 
Dok1, also known as p62dok, is the prototypical member of a family of 7 adaptor 
proteins comprising Dok1 to Dok7. The cytoplasmic protein Dok1 is functionally characterized 
by an N-terminal pleckstrin homology (PH) domain that allows anchorage to the membrane, 
followed by a phosphotyrosine-binding (PTB) domain that is involved in protein-protein 
interactions, and a C-terminal region rich in tyrosine, proline and serine residues (Mashima et al., 
2009). Since p62Dok was first identified as a substrate of p210bcr-abl, v-Abl (Carpino et al., 
1997); (Yamanashi et al., 1997) and many other protein tyrosine kinases, it was therefore termed 
Dok1, for downstream of tyrosine kinase 1 (Bose et al., 2006; DeClue et al., 1993; Mashima et 
al., 2009; Niu et al., 2006; Woodring et al., 2004). Dok1 was functionally identified as a tumor 
suppressor based on several studies that demonstrated an antagonizing role of the adaptor protein 
towards p210bcr-abl-mediated cell transformation in vivo (Di Cristofano et al., 2001; Niki et al., 
2004). An understanding of the physiological tumor suppressor role of Dok1 emerged from mice 
studies, which revealed a significantly accelerated onset of the p210bcr-abl-induced chronic 
myelogenous leukemia (CML), a myeloproliferative disorder of the hematopoietic stem cell, 
upon Dok1 inactivation (Di Cristofano et al., 2001; Niki et al., 2004). In addition, mice with 
combined knockouts of Dok1, Dok2, and Dok3 developed aggressive histiocytic sarcoma 
(Mashima et al., 2010) or lung adenocarcinoma (Berger et al., 2010). 
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The Dok1 gene localizes to human chromosome 2p13, a locus that is prone to genetic 
alterations in various human tumors (Inaba et al., 1991; Nelms et al., 1998; Yoffe et al., 1990). 
Dok-1, Dok-2, and Dok-3 proteins are highly expressed in hematopoietic cells (Di Cristofano et 
al., 2001; Kawamata et al., 2011). In addition, higher expression levels of Dok1 were detected in 
serous epithelial ovarian cancer as compared to normal tissues and this overexpression 
significantly correlated with disease-free survival of serous epithelial ovarian cancer patients 
(Siouda et al., 2012). Dok1 was also shown to be repressed in other forms of cancer including 
head and neck cancer (HNC), lung, liver, and gastric cancers, likewise in Burkitt's lymphoma 
(Balassiano et al., 2011; Lambert et al., 2011; Saulnier et al., 2012). The function of Dok1 is 
regulated upon phosphorylation by a variety of receptor and non-receptor tyrosine kinases 
including the Src tyrosine kinase family members Lck and Fyn (Nemorin and Duplay, 2000), as 
well as tyrosine kinases such as Tec and Bcr-Abl (Gerard et al., 2004; Lee et al., 2004; Liang et 
al., 2002; Noguchi et al., 1999; Woodring et al., 2004). It has also been demonstrated that Src 
phosphorylates Dok1 and prevents its entry into the nucleus (Niu et al., 2006). Recently, Takeda 
et al. identified Dok1 as a substrate of several tyrosine kinases including BRK (Takeda et al., 
2010). 
 
1.7 BRK expression profile in normal and cancer tissues 
Physiological expression of BRK has been reported in a number of epithelial cells, 
including oral (Petro et al., 2004), intestinal (Vasioukhin et al., 1995), prostate (Lee et al., 1998), 
and mammary epithelial cells (Peng et al., 2014a). In addition, BRK is expressed in vascular 
endothelial cells (Haines et al., 2015), melanocytes (Lee et al., 1993), lymphocytes (Kasprzycka 
et al., 2006), normal ovary (Schmandt et al., 2006), and esophageal tissues (Chen et al., 2014). It 
has been reported that BRK expression is initiated as cells migrate away from the proliferative 
zone and begin the process of terminal differentiation (Vasioukhin and Tyner, 1997). 
Overexpression of BRK in mouse keratinocytes resulted in elevated expression of the 
differentiation marker filaggrin during calcium-induced differentiation (Vasioukhin and Tyner, 
1997). Further, a report suggests that BRK is highly expressed in non-dividing villus epithelium 
of small intestine and also detectable in post irradiated crypt cells (Haegebarth et al., 2009; Llor 
et al., 1999).  
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BRK overexpression has also been observed in many cancers, including breast cancers 
(Mitchell et al., 1994), some metastatic melanomas (Easty et al., 1997), colon cancers (Llor et 
al., 1999), squamous cell carcinomas (Petro et al., 2004), prostate cancers (Derry et al., 2003), 
malignant lymphocytes (Kasprzycka et al., 2006), as well as in high-grade serous carcinomas 
and ovarian cancer cell lines (Schmandt et al., 2006). It has also been reported that a detectable 
level of BRK is present in transforming B and T cells as well as cutaneous T-cell lymphomas 
(Kasprzycka et al., 2006). BRK is also expressed in pancreatic cancer and promotes cell 
migration and invasion through ERK signaling cascade (Ono et al., 2014). Additionally, it has 
been reported that BRK is significantly downregulated in esophageal squamous cell carcinoma 
and is associated with a poor prognosis (Chen et al., 2014). However, overexpression of BRK in 
a subgroup of non-small cell lung cancers is associated with a poor prognosis (Zhao et al., 
2013b), suggesting that the role of BRK may be tissue specific. 
 
1.8 Implication of BRK in breast cancer 
BRK is expressed in many breast cancer cell lines and primary breast tumors (Barker et 
al., 1997; Mitchell et al., 1994). However, the expression of BRK is low or absent in the normal 
human breast tissue or at any stage of mammary gland differentiation in the mouse (Llor et al., 
1999). Recently, it has been reported that the activated form of BRK occurs only in mammary 
tumors, and not in normal tissue (Peng et al., 2014a). This suggests that the enzymatic activity of 
BRK is associated with mammary tumor progression. 
It was recently determined that approximately 85% of surgical samples of breast 
carcinomas show BRK mRNA expression (Harvey et al., 2009). The dramatic induction of BRK 
in a significant
 
percentage of human breast tumors, therefore, suggests a role for BRK in the 
etiology of breast cancer. In fact, BRK localizes to chromosome 20q13.3, a region of the genome 
that is frequently amplified in breast cancer (Chin et al., 2006; Harvey and Crompton, 2004). 
BRK overexpression has also been associated with ER-positive status (Zhao et al., 2003) and 
with long-term survival in breast cancer patients (Aubele et al., 2007; Aubele et al., 2009; 
Aubele et al., 2008), suggesting that BRK may play different roles in breast cancer depending on 
the cellular and/or molecular context. These studies, as a whole, propose that although cell 
proliferation and migration are potential molecular processes modulated by BRK in breast 
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cancer, the cellular role of BRK may depend on its activation status and may also be cell type 
specific.  
 
1.9 Physiological role of BRK  
 
BRK (PTK6)-null mice and mouse xenografts as well as recent transgenic mouse models 
have helped in the understanding of the potential physiological role of BRK in tumorigenesis. 
BRK-deficient mice showed delayed and decreased expression of I-FABP, a differentiation 
marker, and enhance proliferation and growth of enterocytes of the small intestine (Haegebarth et 
al., 2006). However, transplantation of BRK alone, ErbB2 alone or both BRK and ErbB2 stably 
overexpressing immortalized pluripotent mammary epithelial cell line (Comma-1D) into mouse 
mammary fat pad induce tumor mass in BALB/c mice, suggesting a role of BRK in 
tumorigenesis (Xing et al., 2008). 
Muller et al. for the first time showed the link of ErbB2 in mammary tumorigenesis 
(Muller et al., 1988). In this study, the rat homolog of HER2/ErbB2 (Neu) was targeted under 
mouse mammary tumor virus (MMTV) promoter to the mouse mammary gland. This MMTV-
Neu mouse spontaneously developed multifocal invasive tumors as early as 12 weeks with 100% 
penetrance (Muller et al., 1988). Additionally, it was shown that polyoma middle T antigen 
induces mammary gland tumorigenesis with 100% penetrance with a latency 1-6 months and 
these tumors showed high lung metastatic potential (Fantozzi and Christofori et al., 2006). 
However, c-Src-induced mammary gland tumorigenesis was not observed when it was targeted 
to the mouse mammary gland under the MMTV promoter (Webster et al., 1995). 
In the first transgenic mouse model, BRK (PTK6) was targeted under the whey acidic 
protein (WAP) promoter for mammary gland specific expression.  Only 30% of these BRK 
transgenic mice developed tumors, with a latency average of 10 months and showed delayed 
involution (Lofgren et al., 2011). Additionally, in another study in which BRK was guided to 
mouse mammary gland under the MMTV promoter, only 11% penetrance was observed with a 
long latency time of 21 months (Peng et al., 2013). Additionally, it was also reported that Ptk6 -
/- mice developed skin tumor with a latency 11 months (Chastkofsky et al., 2015). Further, when 
this MMTV-BRK transgenic strain was crossed with MMTV-Neu (HER2), no significant 
incident of tumorigenesis was observed (whereas 80% MMTV-Neu strain developed tumors 
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within 8 months) (Peng et al., 2013). This was surprising since BRK and HER2 coexpression has 
been shown to have synergistic effect in the induction of cell proliferation and the promotion of 
tumor development (Peng et al., 2013; Xing et al., 2008). In fact, it was observed that the latency 
time was increased for tumor formation in these composite mice (Peng et al., 2013), suggesting 
undetectable involvement of wild type BRK in mammary gland tumorigenesis. 
 
 
2.0 Hypothesis and Objectives 
 
2.1 Hypothesis 
Despite significant progress, the mechanism of BRK overexpression, as well as the role of 
BRK in tumorigenesis, prognosis and in signaling is poorly understood and the physiological 
role of BRK is unknown. Since wild-type BRK does not seem to play a significant role in 
mammary tumorigenesis and the activated form of BRK is observed in breast tumor tissues and 
not the normal mammary gland, it is possible the activated form of BRK plays a major role in 
mammary tumorigenesis. Therefore, we hypothesized that BRK contributes to the mammary 
tumor formation and that the activity of BRK is required for the morphogenesis of mammary 
gland tumors and metastasis of breast cancer in vivo. The overall objective of this project is to 
determine how the activation of BRK affects the cellular and physiological role of this kinase in 
breast cancers. 
 
2.2 Objectives of the project: 
 
1. To determine the effect of BRK activation on cell migration, proliferation and anchorage-
independent cell growth. 
2. To examine the role of BRK activation in tumor formation in the mammary glands of 
mice. 
3. To determine the mechanism of action of BRK in the promotion of cell growth and 
proliferation.  
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3. Materials and Methods 
 
3.1. Antibodies and Reagents.  
The following antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA): anti-BRK (N19, sc-916), anti-ERK1/2 (sc-1647), anti-pERK1/2 (sc-16982), anti-GFP 
(sc-8334), anti-pTyr pY20 (sc-508), anti-p-p38 (sc-17852-R), anti-p38 (sc-535), anti-β-actin (sc-
130300). Both anti-phosphotyrosine (anti-pTyr) clone 4G10 and anti-pBRK (Y342) were from 
Upstate (Lake Placid, NY). Anti-PRMT1 antibody was obtained from Millipore (Billerica, MA, 
USA). ). Anti-Dok1 was a gift from Dr. Ryuji Kobayashi (University of Texas, Austin, USA). 
The anti-Sam68 (AD1) polyclonal antibody was generously given by Dr. Stephane Richard 
(McGill University, Canada). Proteasome inhibitors MG132 or Lactacystin were purchased from 
Calbiochem (MA, USA), cycloheximide from Sigma-Aldrich Corporation (St. Louis, MO) and 
EGF from Upstate (Lake Placid, NY). The reagents that were used in the experiments are listed in 
Table 3.2, and names and addresses of suppliers are listed in Table 3.3. 
 
Table 3.2. List of reagents and suppliers 
 
Reagents Suppliers 
1 kb DNA ladder, N3232S NEB 
4’, 6-diamidino-2-phenylindole (FITS), D9542 Sigma- Aldrich 
100 bp DNA ladder, N3231S NEB 
Acrylamide, 0341 AMRESCO 
Adenosine Triphosphate (ATP), A1205 Teknova 
Agarose I™, 0710 AMRESCO 
Ampicillin, 0339 AMRESCO 
Ammonium persulfate (APS), A3678 Sigma- Aldrich 
Alkaline phosphatase, M0290S NEB 
Aprotinin, A6279 Sigma- Aldrich 
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Bisacrylamide, 0172 AMRESCO 
Crystal violet, 65092A-95 EMD 
Difco™ skim milk, 232100 BD 
dNTP, D0056 GeneScript 
Dulbecco’s Modified Eagle Medium (DMEM), SH30022.01 Thermo Fisher 
Scientific 
Enhanced Chemiluminescence Substrate (ECL), 104001EA PerkinElmer 
Fermtech® Yeast Extract, 1.11926.1000 EMD 
Fetal Bovine Serum (FBS), SH30397.03 Thermo Fisher 
Scientific 
Gelatin, G1890 Sigma- Aldrich 
Glycine, 0167 AMRESCO 
Kanamycin sulfate, 0408 AMRESCO 
Laemmli sample buffer, S3401 Sigma- Aldrich 
Lysogeny Broth (LB) agar, L2897 Sigma- Aldrich 
Methanol, MX0485 EMD 
N,N,N’,N’-Tetramethylethylenediamine (TEMED), 87689 Sigma- Aldrich 
Paraformaldehyde, PX0055-3 EMD 
Phenylmethylsulfonyl fluoride (PMSF), P7626 Sigma- Aldrich 
Polyethylenimine, 25987-06-8 Sigma- Aldrich 
SDS, 151-21-3 Sigma- Aldrich 
Sodium azide, S8032 Sigma- Aldrich 
Sodium chloride (NaCl), 0241 AMRESCO 
T4 DNA ligase, M0202S NEB 
Taq Polymerase, M0273S NEB 
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Tris, 0826 AMRESCO 
Trptone, 1.07213.1000 EMD 
Triton™ X-100, X-100 Sigma- Aldrich 
Trypsin-EDTA, T4049 Sigma- Aldrich 
TWEEN
®
 20, 0777 AMRESCO 
 
Table 3.3. List of names and Addresses of the Suppliers. 
 
Company Name Address 
AMRESCO 
 
North York, Ontario, Canada 
Bio-Rad Hercules, California, USA 
BD 
 
Mississauga, Ontario, Canada 
Cell signaling 
 
Whitby, Ontario, Canada 
Corning 
 
NY, USA 
Dojindo 
 
Rockville, Sunnyvale, USA 
EMD 
 
Madison, Wisconsin, USA 
GeneScript 
 
New Jersey, USA 
Gibco 
 
Burlington, Ontario, Canada 
Invitrogen 
 
Burlington, Ontario, Canada 
New England Biolab (NEB) 
 
Mississauga, Ontario, Canada 
Olympus 
 
Richmond Hill, Ontario, Canada 
Pall Corporation 
 
Washington, NY, USA 
PerkinElmer 
 
Boston, Massachusetts, USA 
Qiagen 
 
Mississauga, Ontario, Canada 
Santa Cruz 
 
Santa Cruz, California, USA 
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Sigma-Aldrich 
 
Oakville, Ontario, Canada 
Teknova 
 
Hollister, California, USA 
Thermo Fisher Scientific 
 
Whatham, Massachusetts, USA 
VWR 
 
Mississauga, Ontario, Canada 
Whatman 
 
Piscataway, New Jersey, USA 
 
3.2. Cell cultures 
HEK293, BT20, MCF-10A, AU565, MDA-MB-231, MDA-MB-435, MDA-MB-468, 
T47D, HBL100, MCF7 and SKBR3 cells were originally obtained from the American Type 
Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in high glucose (4.5 
g/l), Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% bovine calf serum 
(Thermo Scientific, Logan, Utah, USA) and containing 4 mM L-glutamine, 100 units/mL 
penicillin, 100 µg/mL streptomycin (Sigma-Aldrich). MCF10A cells (ATCC, Manassas, VA, 
USA) were cultured in DME/F-12 1:1(1X) medium (Thermo scientific) containing 5% horse 
serum (Sigma-Aldrich, St Louis, USA), 20 ng/mL EGF (Upstate, Lake Placid, NY, USA), 0.5 
µg/mL hydrocortisone (Sigma-Aldrich), 100 ng/mL cholera toxin (Sigma-Aldrich, St Louis, 
USA), 50 U/mL penicillin, and 50 mg/mL streptomycin as well as 10 ng/mL insulin (Sigma-
Aldrich, St Louis, USA), as described by Debnath et al. (Debnath et al., 2003).  
 
3.3. Mammalian cell expression and immunoprecipitation 
HEK293 cells were maintained in DMEM containing 10% fetal bovine serum, 50 U/mL 
of penicillin-streptomycin. Cells were rinsed and supplemented with a fresh serum-free culture 
medium just before transfection. The cells were transiently transfected with 1% 
Polyethylenimine “Max” (PEI) (Polysciences Inc., Warrington, PA, USA) at a ratio of 3:1 
reagent to DNA with the total amount of DNA being 2.5 µg per well in six-well dishes. For each 
well, 2.5 µg of DNA was added to 107.5 µl of sterile 0.15 M NaCl in a microcentrifuge tube and 
vortexed gently for 10 sec. 15 µl 1% PEI was added to the DNA mixture and vortexed gently for 
10 sec. The DNA-PEI complex was then incubated for 10 min at room temperature. The mixture 
was added dropwise to wells containing 2 mL of complete media and the plates incubated at 37 
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o
C. Cells were washed 4 h after transfection, then cultured in complete media for an additional 
16-48 h. 
Whole cell lysates were directly prepared in 2x Laemmli buffer ((Sigma-Aldrich, St 
Louis, USA). For immunoprecipitation, cells were washed with cold 1x Phosphate-buffered 
saline (PBS), lysed with freshly prepared lysis buffer (20 mM Tris, pH 7.5, 1% triton (TX-100), 
150 mM NaCl, protease inhibitors: Aprotinin 5 mg/L and 0.1 mM PMSF) containing 0.3 mM 
sodium orthovanadate (Enzo Life Sciences). Lysates were prepared by incubating the harvested 
cells in ice-cold lysis buffer for 30 min, followed by centrifugation for 10 min at 14 k rpm. 
Supernatants were collected and transferred into fresh tubes and incubated with 1 µg of the 
appropriate antibody and maintained on a gyrorotator for 1 h at 4 
o
C. 20 µl of Protein-A agarose 
beads were then added to the samples and incubated for another 40 min on the gyrotator at 4
 o
C. 
The beads were washed twice with ice-cold lysis buffer and 1x PBS and the immunoprecipitated 
proteins were resolved via SDS-PAGE.  
 
3.4. Generation of stable cell lines 
We generated two sets of stable cell lines, BRK-overexpressing cells and BRK-
knockdown cells. To the cells stably expressing BRK, an amphotropic HEK293 derived Phoenix 
packaging cells were used to package pBabe-puro retroviral system. The packaging cells were 
cultured on 10 cm, gelatin-coated plates in 10 mL of DMEM medium supplemented with 10% 
BCS. For viral production, the packaging cells in a 10 cm plate were transfected with 10 μg of 
retroviral DNA using 1% PEI (Polysciences, Inc). The transfection mix contained the plasmid 
and 60 μL of 1% PEI plus 430 μL of 0.15 M NaCl. Virus-containing supernatant was collected at 
24 h and 48 h time points, filtered through 0.45 μm syringe filter, aliquoted and used 
immediately or stored at -80 °C. To infect MDA-MB-231 cells, the virus-containing supernatant 
was supplemented with 10 μL polybrene (Sigma-Aldrich, St Louis, USA), and overlaid on the 
target cells. After overnight incubation with the viral supernatant, this was changed to fresh 
culture medium. Pools of MDA-MB-231 cells stably expressing GFP alone, GFP-BRK-WT and 
GFP-BRK-YF fusions were selected with puromycin (Sigma-Aldrich, St Louis, USA). 
Expression of EGFP from the GFP-tagged BRK was detected by fluorescence microscopy 48 h - 
72 h post-infection.  
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To produce a stable BRK knockdown cell line we used BRK-expressing parental breast 
cancer cell lines BT20 and SKBR3. This knockdown experiment was performed according to the 
manufacturer’s protocol by using shRNA lentiviral vector plasmids from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). The shRNA plasmids generally consist of a pool of three 
to five lentiviral vector plasmids, each encoding target-specific 19-25 nucleotides short hairpin 
RNAs (shRNAs) designed to knockdown gene expression.  As controls, the cells were infected 
with a control shRNAs or with a GFP alone control plasmid. A set of three shRNAs was used to 
complete this knockdown process. 1) GFP-Control plasmid that allowed the confirmation of the 
transduction efficiency by expressing GFP, detectable by fluorescence microscopy. 2) Control-
shRNA plasmid that encodes a scrambled shRNA sequence, which does not lead to the specific 
degradation of any mRNA. 3) BRK-shRNA lentiviral vector plasmids, which contains target-
specific 19-25 nucleotides in shRNA, designed to knock down BRK gene expression. 
Transfected cells were selected using puromycin (Sigma-Aldrich, St Louis, USA).  
 
3.5. RT-PCR and qPCR  
Total RNA was extracted using the RNeasy mini plus kit (Qiagen, Maryland, USA). 
Quantity and quality of RNA were determined spectrophotometrically. 1 μg of RNA was utilized 
for cDNA synthesis using the iScript cDNA Synthesis kit (Bio-Rad Inc., Hercules, CA) 
according to manufacturer’s protocol. In brief, 1 µg of RNA was added to a mix containing 4 µL 
5X iScript Reaction Mix and 1 µL iScript Reverse Transcriptase in a final volume of 20 µl. Then 
the cDNA synthesis reaction was completed by incubating at 25 °C for 5 min, followed by 30 
min at 42 °C and 5 min at 85 °C.  Samples were either used immediately or preserved at -20 °C. 
Total RNA was used as a template for the synthesis of cDNA using the iScript cDNA Synthesis 
kit (Bio-Rad) according to manufacturer’s specifications. Briefly, 1 µg of RNA was added to a 
mix containing 4 µL 5X iScript Reaction Mix, 1 µL iScript Reverse Transcriptase and 1 µg RNA 
in a final volume of 20 µL. Synthesis of cDNA was completed by incubation at 25 °C for 5 min, 
followed by 30 min at 42 °C and 5 min at 85 °C.  Samples were used immediately or stored at -
20 °C. 
Real Time PCR- quantification of cDNA was performed using a fluorescence-based 
detection system (Step One Plus, Applied Biosystems).  Using Dok1 primers, PCR was 
performed in a final volume of 10 μL containing 0.3 μL cDNA, 33 ng of each primer and 5 μL of 
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SsoFast EvaGreen Supermix (Bio-Rad Inc., Hercules, CA). Cycling conditions were: 20 sec at 
95 °C followed by 40 cycles of 95 °C for 3 sec, and 58.2 °C for 30 sec.  Data was analyzed by 
the Ct method. 
qPCR was performed using 50 ng of cDNA in 50 μL reaction mixtures containing 0.02 
mM deoxynucleoside triphosphate (dNTP) mix (GenScript, NJ, USA), 10× Standard Taq buffer 
(New England Biolabs, MA, USA), 0.0125 U/μL of Taq DNA polymerase (New England 
Biolabs, MA, USA), and 0.4 mM each primer. Primers specific for human Dok1 and reference 
RPL 13A were the following:  Dok-1 forward 5′-CTA CAA CCC TGC CAC TGA TGA CTA-3′ 
and reverse primer 3′-CTA GAG AGC CCA CAG TCC CAG CTC-5′; RPL13A forward 5′-CAA 
GGT GTT TGA CGG CAT CC-3′; and reverse primer, 3′ GCT TTC TCT TTC CTC TTC TCC  
5′. Reaction mixtures containing cDNA prepared from HEK 293, HEK293-GFP-BRK-WT and 
HEK293-GFP-BRK-YF. The cycling program run was 95 °C for 2 min, followed by 35 PCR 
cycles (95 °C for 30 sec, 60 °C for 15 sec, 72 °C for 45 sec) and a final extension for 5 min at 72 
°C. PCR products were run in a 1% agarose gels and visualized by GelRed staining using the 
AlphaDigiDocTM, Genetic Technologies, Inc, USA. 
 
3.6. Dok1 expression vectors and mutagenesis  
GFP-Dok1 construct, a gift from Dr. Bakary S. Scylla, Lyon, France, was used to 
generate GFP-Dok1 deletion mutants. Five pairs of primers were used to amplify five Dok1 
cDNA variants of progressively differing lengths which were then cloned at the C-terminal of the 
GFP sequence in the EcoRI and SmaI sites of the pEGFP-C1 vector backbone: DokΔ1:  5′-AGT 
GAA TTC GGA CGG AGC AGT GAT GGA A-3′ and 3′- ATT CCC GGG TCA AGT CTC 
AAC TGC CTG-5′; DokΔ2:  5′-AGT GAA TTC GGA CGG AGC AGT GAT GGA A -3′ and 3′-
ATT CCC GGG TCA CTT CCG TTG TAC TCC-5′; DokΔ3:  5′-AGT GAA TTC GGA CGG 
AGC AGT GAT GGA A-3′ and 3′-ATT CCC GGG TCA CTT GGC CTT CAG CAA-5′; 
DokΔ4: 5′-AGT GAA TTC GGA CGG AGC AGT GAT GGA A and 3′-ATT CCC GGG TCA 
CTT CAC CCG AGC TTG-5′; DokΔ5: 5′-AGT GAA TTC GGA CGG AGC AGT GAT GGA 
A-3′ and 3′-ATT CCC GGG TCA CTT GGG AGC AAG GAG-5′. The Dok1 C-terminal 
segment extending from the IRS-PTB and spanning 222 amino acids was cloned into the EcoRI - 
NotI sites of the pGEX-5-x-3 vector, using the primers: 5′-ATA GAA TTC CGA CGG AGC 
AGT GAT GGA A-3′ and 5′-ATA GCG GCC GCT CAG GTA GAG CC-3′. The Dok1 cDNA 
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was cloned at the C-terminus of the mCherry (a generous gift from Dr. Scot Stone, University of 
Saskatchewan, Saskatoon, SK, Canada) sequence in the BglII and SmaI restriction sites of the 
pmCherry-C1 vector backbone using the primers: 5′-AAA AGA TCT ATG GAC GGA GCA 
GTG ATG and 3′-ATT CCC GGG TCA GGT AGA GCC CTC TGA. The composite mcherry-
Dok1 cDNA was subcloned into the KpnI and NotI sites of a pShuttle-CMV plasmid by using a 
set of primers 5′-AAA GGT ACC GTC GCC ACC ATG GTG AGC AAG GGC GAG and 3′-
ATA GCG GCC GCT CAG GTA GAG CC.  Site-directed mutations of human Dok1 were 
introduced using a Quick Change Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) 
according to the manufacturer's instructions. All constructs were verified by sequencing. 
 
3.7. Subcellular fractionation 
Cells were fractionated into four different subcellular parts: cytosolic, membrane, 
nuclear, and cytoskeletal matrix fractions, using ProteoExtract Subcellular Proteome Extraction 
Kit (EMD, 539790) following the manufacturer’s protocol. In brief, cells were washed twice 
with wash buffer, then cells were subjected to extraction buffer I to elute cytosolic fraction, and 
extraction buffer II for the membrane fraction. Benzonase Nuclease was applied to collect the 
nuclear fractions and finally cytoskeletal matrix was obtained by using extraction buffer IV. All 
the fractionated proteins were resolved via SDS-PAGE and analyzed by immunoblotting. 
 
3.8. Immunoblotting 
Total cell lysate prepared from transfected or non-transfected cells were subjected to 
sodium dodecyl sulfate 10% polyacrylamide gel electrophoresis (SDS-PAGE) and 
electrophoresed proteins were transferred to nitrocellulose membranes (Bio-Rad). In general, 
membranes were blocked for 30-45 min in a 5% non-fat dry milk or in 1.0% bovine serum 
albumin when phosphotyrosine antibodies were used. The membranes were incubated overnight 
at 4 °C with primary antibodies prepared according to manufacturer’s instructions. Polyclonal 
goat HRP-conjugated secondary antibodies against mouse or rabbit IgG (Bio-Rad Inc., Hercules, 
CA, 1:10000 dilution) were incubated on membranes for 1 h at 4 °C, followed by 
chemiluminescence (ECL) detection using the ECL kit (DuPont, Wilmington, DE, USA) and 
protein bands visualized by autoradiography.  
 
 30 
 
3.9. Cell migration (Wound healing or Scratch) assay 
Cells were seeded into 6 well plates at a density of 1×10
6
 cells /well and cultured until 
80-90% confluent in the culture medium. A 1000 µL sterile pipette tip was used to scratch a 
constant-diameter stripe or wound diagonally in the confluent monolayer. The medium and cell 
debris were aspirated away and replaced with a fresh culture medium. After wounding 0, 12, 24, 
36 and 48 h later plates were imaged using Olympus 1X51 inverted microscope (Olympus 
America, Center Valley, PA) with a 10X phase contrast objective. These experiments were 
repeated at least three times. Values were means ± SD from at least three independent 
experiments. 
 
3.10. Transwell assay  
The cells were cultured in serum free-medium overnight, harvested and resuspended in 
serum-free medium. A suspension of cells (5×10
5 
cells) was added to the upper chamber of 24-
well Transwell plates (Corning Incorporated, Corning, NY, USA) and a complete medium 
(containing 10% FBS) was added into the bottom chamber of the Transwell plate (6.5 mm 
diameter and 8.0 µm). The cells were then incubated at 37 °C and 5% CO2 for 24 h and the non-
migrated cells were removed by using a sterile cotton swab from the upper surface of the filter. 
The cells that migrated through the chamber onto the lower surface of the filter were fixed with 
paraformaldehyde and stained with crystal violet for 30 min. The number of migrating cells was 
counted (Five high power fields were counted per filter to score for migration) under an 
Olympus 1X51 microscope and the count was scored as migration in comparison to parental 
control cells.  
 
3.11. Soft agar anchorage-independent growth assay 
MDA-MB-231 cells were suspended in a top layer of DMEM-10% calf serum containing 
0.35% low melting point agarose (Sigma-Aldrich, St Louis, USA) at 42 °C and overlaid onto the 
solidified 0.6% agarose layer containing a DMEM-10% FBS. After 3 weeks of incubation at 37 
°C, the numbers of colonies formed were counted in triplicate wells from five fields 
photographed with a 10× objective. 
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3.12. Mouse tumorigenicity (Xenograft) assay  
Xenograft experiments were conducted in 6-7 week old female athymic nude mice, 
purchased from the National Cancer Institute, Frederick, MD. MDA-MB-231 cells expressing 
each of the GFP-BRK fusions including GFP alone as stable pools were harvested in PBS and 
resuspended in Matrigel (BD Biosciences). For each injection, 2.5 × 10
6
 MDA-MB-231 cells in a 
100 μL volume of Matrigel were injected subcutaneously bilaterally into mammary fat pad 
number 5 according to standard injection procedures, with 4 animals injected per cell line. Once 
tumors were palpable (about 2 weeks after injection of tumor cells), mammary primary tumor 
growth rates were monitored and analyzed by measuring tumor length (L) and width (W), for 
about eight weeks. Tumor size was assessed by measurements with an electronic caliper. 
Volume was calculated as 0.50 × length × width
2
. Nude mouse xenograft experiments were 
performed under an animal protocol approved by the Animal Care Unit and Committee of the 
University of Saskatchewan. Mice were sacrificed in a humane manner when the tumor size 
exceeded the approved limit by animal ethical authority. 
 
3.13. Recombinant GST-fused protein expression and GST-pull-down assay 
GST pull-down assays were performed as previously described (Chen et al., 1999). GST-
tagged constructs (GST, GST-BRK-SH3 and GST-BRK-SH2 previously generated by the 
Lukong lab) were expressed in E. coli (BL21 strain), and cultured in 2XYT media. Protein 
induction was initiated by the addition of 1 mM IPTG to the bacterial cultures at an optical 
density (600 nm) of 0.6. Bacterial cells were then lysed by sonication in ice-cold 1x PBS buffer 
containing protease inhibitors: 1 µg/mL aprotinin, and 0.01% phenylmethanesulfonyl fluoride 
(PMSF), supplemented with a protease inhibitor cocktail comprising 23 mM AEBSF (4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride), 2 mM Bestatin, 100 mM EDTA 
(Ethylenediaminetetraacetic acid), E-64 0.3 mM trans-epoxysuccinyl-L-leucylamido-(4-
guanidino) butane (E 64), 0.3 mM Pepstatin A, in dimethylsulfoxide (DMSO) (P8465, Sigma-
Aldrich Corporation, St. Louis, MO). Lysates were then incubated with Glutathione Sepharose 
beads (GST, Novagen, CA, USA.). In brief, the pull-down experiments were carried out using 
GST, GST-BRK-SH3 and GST-BRK-SH2 proteins immobilized on glutathione-Sepharose 
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beads, which were incubated with cell lysates followed by 3 times wash with ice cold PBS., The 
bound proteins were then resolved by SDS-PAGE as described above. 
 
3.14. In vitro kinase assay  
In vitro kinase assays were performed using 100 ng GST-BRK and a 10 μL volume of 
substrate (GST-C-terminus Dok1, residues 260-481) in a reaction volume of 50 µl comprising 20 
μL kinase buffer (25 mM MOPS, pH 7.2, 2.5 mM DTT, 12.5 mM β glycerol-phosphate and 5 
mM EGTA (Signalchem, Richmond, BC, Canada) with or without 200 µM ATP. The reaction 
mixture was incubated at 30 
o
C for 30 min to complete the kinase reaction and eventually 
terminated by the addition of 2x Laemmli sample buffer. The samples were then boiled at 100 
o
C 
and resolved via SDS-PAGE (as described above). 
 
3.15. In vivo ubiquitination assays  
GFP-BRK-YF expressing HEK293 stable cells were transfected with HA-tagged 
ubiquitin and/or Dok1 plasmids and the cells treated with 10 μM MG132. The cell lysates were 
incubated with the primary rabbit anti-Dok1 antibody followed by protein-A agarose conjugation 
and immunoblotting with anti-HA antibody to detect ubiquitinated Dok1. 
 
3.16. Statistical analysis 
For statistical analysis, one-way and two-way ANOVA followed by a post hoc Newman-
Keuls test was used for multiple comparisons using GraphPad Prism version 5.04 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com.The results are given as the 
means ± SD. P ≤ 0.05 was considered statistically significant. 
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4. RESULTS 
 
The results of this thesis are divided into two major parts under the following headings:  
4.1 Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in 
vivo  
4.2 BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell 
proliferation and migration 
 
4.1. Constitutive activation of breast tumor kinase accelerates cell migration 
and tumor growth in vivo 
 
BRK is a non-receptor tyrosine kinase overexpressed in most human breast tumors and 
breast tumor cell lines. However, a positive or negative BRK activity regulator has not been 
identified. Studies have indicated that BRK is activated upon stimulation of the epidermal 
growth factor receptor (EGFR) and insulin-like growth factor-I receptor (IGF-IR) (Lukong et al., 
2003; Lukong et al., 2005). Lukong et al. and others previously demonstrated that mutation of 
tyrosine 447 to phenylalanine results in a constitutively active variant of BRK whose activity is 
significantly higher than BRK-WT (Lukong et al., 2005; Qiu and Miller 2002; Lukong et al., 
2009). During the preparation of this thesis, a newly published report showed that the activated 
form of BRK is found only in breast tumors and not in the normal mammary gland (Peng et al., 
2014a). This implies that the activation of BRK may play a prominent role in breast cancer 
tumorigenesis. 
To understand the cellular and physiological significance of full activation of BRK, we 
first assessed the activity of various BRK mutants followed by the generation of stable cell lines 
expressing various BRK variants including the constitutively active form of BRK (BRK-Y447F).  
The stable cell lines were subjected to cell proliferation, migration and colony formation assays. 
Since the function of active BRK in tumors is not fully understood, we have also investigated the 
role of constitutively active BRK in tumor formation in Xenograft mice. We present evidence 
that full activation of BRK significantly enhances the cellular and physiological properties of 
BRK, which include cell proliferation, migration and tumor formation.  
 34 
 
4.1.1. Results 
4.1.1.1. Tyr447Phe BRK mutant is significantly more active than the wild-type BRK 
It was previously reported that some BRK mutants displayed varying degrees of activities 
compared to wild-type BRK when expressed in human embryonic kidney HEK293 cells (Qiu 
and Miller, 2004). These included W44A, SH2 and SH3 deletion mutants (ΔSH2 and ΔSH3), 
and Y342A, K219M, and Y447F mutants (Figure 4.1A). Trp44 is a conserved residue in the SH3 
domain previously shown to make contacts with proline residues in the linker region and further 
stabilize the inactive conformation of BRK. Mutation of Trp44 to alanine (W44A) was shown to 
abolish the SH3–linker interaction (Kim et al., 2007) and enhance enzyme activity (Qiu and 
Miller, 2004). Tyr342 is the major autophosphorylation site necessary for full activation of BRK, 
while mutation of Lys219, an essential active site residue, to methionine abrogates catalytic 
activity (Qiu and Miller, 2004). In order to understand the role of activated BRK in various 
cellular processes, we first generated GFP-tagged BRK wild-type (WT) and constitutively active 
BRK Y447F constructs. To ensure that the GFP tag did not interfere with the BRK enzymatic 
activity, we compared the activities of various non-tagged BRK constructs to those of GFP-
tagged constructs in transfected HEK293 cell lysates (Figure 4.1B). The lysates were subjected 
to SDS-PAGE analysis followed by immunoblotting using anti-phosphotyrosine antibody, pY20, 
designed specifically to recognize phosphorylated tyrosine residues and using phospho-BRK 
antibody designed to recognize autophosphorylation of BRK at Tyr342. As previously shown, 
BRK mutants ΔSH3, K219M and Y342A displayed significantly lower or no activity as 
compared to the BRK WT (Qiu and Miller, 2004) as demonstrated by the degree of staining by 
pY20 (Figure 4.1B, top panel, compare lanes 4, 5 and 7 to lane 1). The BRK mutant, W44A 
showed a slightly lower activity as compared to the WT. As anticipated, the ΔSH2 (lane 3) and 
Y447F (lane 6) mutants displayed the highest levels of activity, confirming that docking of 
pY447 to the SH2 domain is equally important in BRK to stabilize an inactive conformation. In 
the context of the present work, it is important to note that both GFP-BRK-WT (lane 9) and 
GFP-BRK-Y447F (lane 10) displayed catalytic activity and that, as expected, GFP-BRK-Y447F 
showed a much higher level of substrate phosphorylation compared to GFP alone (lane 8) or 
GFP-BRK-WT (lane 9). These activity results using pY20 were corroborated with anti-phospho-
BRK staining, although it is not clear why substrate phosphorylation by GFP-BRK ΔSH2 (lane  
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Figure 4.1. Tyr447Phe BRK mutant is notably more active than the wild-type BRK. (A) 
Schematic representation of BRK. The diagram shows the functional domains and the positions 
of some of the key residues mutated in this study. (B) The activity of BRK and BRK mutants in 
transfected HEK 293 cells. Wild-type (WT) BRK and BRK mutants, non-tagged and GFP-
tagged, were transfected and expressed in HEK 293 cells as described in “Materials and 
methods”. Cell lysates were subjected to immunoblot analysis with anti-phosphotyrosine 
antibody (pY20) and anti-BRK and anti-phospho-BRK (pTyr342) antibodies. Anti-β-tubulin 
served as a loading control. 
 
 
3) was not detected by this antibody. Taken together, these data substantiate that BRKY447F is 
notably more active than the wild-type and that a GFP tag did not interfere with the BRK’s 
catalytic activity. 
 36 
 
4.1.1.2. Constitutively active BRK enhances ERK activation and increases cell proliferation 
 
In order to better understand the role of BRK in mammary gland tumorigenesis and to 
gain an insight into the role played by the constitutively active form of BRK in cell growth and 
proliferation, we generated three sets of stable cell lines by retroviral infections. Each cell line 
stably expressed GFP alone, GFP-BRK-WT or GFP-BRK-YF. We utilized BRK-negative cell 
lines, which include epithelial cell lines MCF10A and MDA-MB-231 (Figure 4.2A), as well as 
HEK293 cell line (Lukong et al., 2005). MCF10A is an immortalized mammary epithelial cell 
line and MDA-MB-231 cells are estrogen receptor-negative, highly invasive breast cancer cell 
line. All of the cells were generated as pooled populations of puromycin-resistant cells to avoid 
any clonal variations. We subjected cell lysates from the stable cells to immunoblotting with 
anti-GFP and anti-BRK and demonstrated that stable MCF10A express equivalent levels of GFP-
BRK-WT and GFP-BRK-YF (Figure 4.2B). More importantly, we analyzed the cell lysates for 
their relative levels of tyrosine phosphorylation using an anti-phosphotyrosine antibody to ensure 
that the activity in the BRK-YF stable cells was higher than the wild-type as expected. As shown 
in Figure 4.2C, overexpression of both BRK-WT and BRK-YF resulted in high phosphorylation 
of endogenous substrates as compared to the control cells. As expected, BRK-YF stable cells 
displayed a much higher level of tyrosine kinase activity as compared to BRK-YF samples 
(Figure 4.2C). Similar results were also obtained from both MDA-MB-231 and HEK293 stable 
cell lines (Figure 5.6). 
Kamalati et al. demonstrated that exogenous expression of wild-type BRK in normal 
mammary epithelial cells enhanced mitogenic signaling (Kamalati et al., 1996). Lukong et al. 
and others have shown that EGF-induced activation of BRK contributed to the phosphorylation 
of BRK substrates Sam68 and paxillin (Chen et al., 2004; Lukong et al., 2005). Using our 
MCF10A stable cell model system, we first investigated whether constitutive activation of BRK 
is accompanied by enhanced activation of mitogenic signaling in unstimulated cells. For this 
experiment, cell lysates from stable cell lines expressing GFP, GFP-BRK-WT or GFP-BRK-YF,  
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Figure 4.2. Constitutively active BRK enhances ERK activation and increases cell proliferation. 
(A) BRK is not expressed in normal mammary gland epithelial cell lines. BRK expression in the 
indicated breast cancer cell lines (lanes 3-11) and normal mammary epithelial cell lines (lanes 1 
and 2) was detected by immunoblotting. β-actin was used as a loading control. (B) and (C) 
Stable cell lysates were analyzed by immunoblotting using an anti-BRK, anti-GFP and anti-
phosphotyrosine antibody, pY20. Protein arginine methyltransferase 1 (PRMT1) served as a 
loading control.  (D) and (E) Stable cell lysates were subjected to immunoblot to detect ERK1/2 
and pERK1/2 by using anti- ERK1/2 and anti-pERK1/2 antibodies. PRMT1 served as a loading 
control. (E) Growth assay for MCF10A cells stably expressing BRK-YF, WT and vector alone 
control cell lines. 
 
 
as well as parental cell line were analyzed by immunoblotting for Erk1/Erk2 activation (Figure 
4.2D). Indeed, ERK activation, as demonstrated by the level of ERK1/2 phosphorylation was 
observed in both GFP-BRK-WT and GFP-BRK-YF samples (Figure 4.2D) and the presence of 
constitutive active BRK-YF resulted in a more pronounced activation of ERK compared to the 
WT counterpart. The GFP control cell lysates only showed background pERK as compared to 
lysates that were harvested from either the BRK-WT or YF stable cell lines. These data 
demonstrated that overexpression of BRK resulted in the activation of ERK signaling even in the 
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absence of EGF stimulation. Moreover, BRK activation was found to induce phosphorylation of 
ERK, thereby stimulating mitogenic signaling. Since activation of the Ras / ERK pathway plays 
a pivotal role in cell proliferation and is associated with a gain-of-function mechanism in breast 
carcinogenesis (Krishna and Narang, 2008), we next examined the effect of constitutive 
activation of BRK on cell growth. The MCF10A cell lines were plated at low density and cell 
number counted every 6 h for 48 h. Compared to the WT and control cell lines, we observed a 
significant increase in cell number in the pools of cells expressing BRK-YF as early as 6 h after 
the cells were plated (Figure 4.2E). A more modest ERK activation and increased cell growth 
was also observed in MDA-MB-231 cells stably expressing BRK-YF. No significant difference 
in cell viability was observed between the different cell types. Taken together, these data show 
that BRK is an upstream effector in the ERK pathway and constitutive activation of BRK results 
in increased ERK activation that corresponds with enhanced cell proliferation. 
 
4.1.1.3. Constitutive activation of BRK is associated with increased cell migration and 
invasion  
Several studies have shown that BRK contributes to the processes of migration and 
invasion that characterize the metastatic potential of breast cancers. For example, it was 
previously shown that BRK contributed to cell migration and proliferation by enhancing EGF-
mediated phosphorylation of paxillin and activation of Rac1 via CrkII (Chen et al., 2004). 
Similarly, BRK knockdown by RNA interference was shown to impair the migration of breast 
cancer cells (Harvey and Crompton, 2003; Lukong et al., 2005; Ostrander et al., 2007). In order 
to address the role of constitutive activation of BRK in cell migration, we employed both the 
wound-healing and Transwell migration assays. Cells were induced to migrate into a wound 
created by scratching confluent cultures with a pipette tip to examine the migration of MDA-
MB-231 stable cell lines expressing GFP alone, GFP-BRK-WT or GFP-BRK-YF (Figure 4.3). 
MDA-MB-231 cells were selected for this experiment because of their characterized high 
migratory potential (Gruber and Pauli, 1999). Closure of wounded area was monitored for 36 h. 
As shown in Figure 4.3, the open area was rapidly covered by the BRK-WT and BRK-YF cells  
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Figure 4.3. Constitutive activation of BRK accelerates cell migration in wound healing assays.  
(A) MDA-MB-231 stable cells seeded into 6-well plates at 80-90% confluence. The wound of 
approximately 1 mm in width was scratched with a 200 μL pipette tip.  Wound closure was 
monitored at the indicated time intervals and imaged with phase contrast microscopy on an 
inverted microscope (Olympus 1X51 using a 10X phase contrast objective). The migration assay 
was performed in three independent experiments. (B) The open area (scratch) was quantified 
with TScratch software. The p-values were determined for control and stably transfected cells 
and set at p ≤ 0.05 for statistical significance. 
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in comparison to control cells transduced with the empty vector. Moreover, constitutively active 
BRK-YF accelerated wound closure more efficiently at 24 h than the BRK-WT cells (Figure 
4.3A). The BRK-YF cells migrated into the wounded area and almost completely closed the 
wound within 48 h. Quantification of wound closure is represented in bar diagram in Figure 
4.3B. The quantified open area in vector control cells were reduced from 100% to only 81%, the 
open area of BRK-WT cells were shrunk from 100% to 24%, while the constitutively active 
BRK-YF cells were dramatically reduced from 100% to 6% (Figure 4.3B). These data suggest 
that activation of BRK significantly accelerates motility of the MDA-MB-231 cells.  
In order to validate the effects of BRK on cell migration by wound healing, we silenced 
BRK in two BRK-positive breast cancer cell lines BT20 and SKBR3. The BT20 is a triple 
negative breast cancer cell line, while SKBR3 is a HER2-positive breast cancer cell line (Neve et 
al., 2006). To achieve stable BRK knockdown, the BT20 and SKBR3 cells were transfected with 
lentiviral vector plasmids encoding BRK-specific short hairpin RNAs (shRNAs) and cell lysates 
analyzed by immunoblotting using anti-BRK antibodies (Figure 4.4A and 4.4D). The degree of 
knockdown of BRK was quantified to 67% in BT20 cells and to 87% in SKBR3 cells as 
compared to their respective cell lines transfected with the shRNA, scrambles control or parental 
cell lines (Figure 4.4A and 4.4D, right panels). The confluent cell lines were scratched and 
wound healing examined over a period of 48 h. As shown in Figure 4.4B and 4.4E, BRK 
knockdown resulted in a significant delay in wound closure as compared to control cells after 48 
h. The quantified score of open area showed that open area in the control cells was reduced from 
100% to 17% after 48 h, whereas BRK knockdown in BT20 cells only reduced to 56% (Figure 
4.4C). Similarly, in SKBR3 control cells the open area was reduced from 100 to 23% and only 
57% in the knockdown cells (Figure 4.4E). These data suggest that silencing of BRK reduced the 
motility of breast cells irrespective of their molecular subtype. 
As an independent means of measuring cell motility, we further investigated the 
contribution of activated BRK in cell migration in vitro by employing the Transwell migration 
assays. These assays were performed using MDA-MB-231 cells stably expressing BRK-WT and 
BRK-YF and breast cancer cell lines BT20 and SKBR3 in which BRK is stably knockeddown. 
For each assay, the stable cells including the controls were plated in the upper chamber in serum-
free media. An 8 µM polycarbonate membrane separated the upper chamber from a lower 
chamber containing complete media. After 24 h incubation cells on the top of the membrane 
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were removed by swiping and the membrane was rinsed and stained with trypan blue. Migrated 
cells  
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Figure 4.4. Stable knockdown of BRK significantly suppresses migration of breast cancer cells 
in wound healing assays. (A) and (D) Efficient knockdown of BRK in BT20 breast cancer cells. 
(B and C) and (E and F) BRK knockdown significantly suppresses migration of both BT20 and 
SKBR cells. The stable knockdown cells were analyzed for cell migration using the wound-
healing assay in 6-well plates as described in Figure 3 legend. The open area (scratch) was 
quantified with TScratch software. The p-values were set at p ≤ 0.05 for statistical significance. 
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on the underside of the membrane were counted under a microscope, in four different viewing 
fields, at 20x magnification. As shown Figure 4.5A, both BRK-WT and BRK-YF induced a 
dramatic increase in cell migration compared to the GFP alone control or the parent cell line. 
BRK-WT enhanced migration as expected, in both BT20 and SKBR3 cell lines migration was 
attenuated by >50% in BRK-shRNA than the controls, while BRK-YF induced a marked 
increase in cell migration by over three-folds as compared to the control cells. To further validate 
the involvement of BRK in migration, we performed Transwell migration assays with BT20 and 
SKBR3 stably depleted of BRK by shRNA (Figure 4.5B and 4.5C). Cell migration across the 
Transwell was significantly decreased by the depletion of BRK in both the BT20 and SKBR3 
cell lines using shRNA as compared to either the control shRNA transfected cell lines or the 
parental cell lines. Collectively, these data suggest that BRK contributes to the basal cell 
migration of BT20 and SKBR3 cells and also that full activation of BRK induces cell migration.  
 
 
 
 45 
 
 
Figure 4.5. Transwell assays demonstrating the effect of BRK on cell migration. (A) Migration 
of BRK stable MDA-MB-231 cell lines expressing GFP-BRK-WT, or constitutively active GF-
BRK-YF or GFP alone were evaluated in 24-well Transwell polystyrene membrane with 8µm 
size pores. Migrated cells were fixed with paraformaldehyde, stained with crystal violet for 30 
min and the number of migrating cells was counted scored in relative units. (B) and (C) BRK 
knockdown significantly suppresses migration of BT20 and SKBR breast cancer cell lines. The 
stable knockdown BT20 and SKBR breast cancer cell lines were prepared as described in Figure 
4 legend and analyzed for migration by Transwell assay as described above. All results are the 
mean (± SD) of more than three separate experiments. Statistical analysis *p ≤ 0.05 and ***P ≤ 
0.0001. 
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4.1.1.4. Activated BRK promotes tumorigenicity in vitro and in vivo 
Growth in anchorage-independent conditions is a hallmark of tumorigenicity and 
invasiveness in several cancer cell types (Simpson et al., 2008; Tsatsanis and Spandidos, 2004). 
Since we have shown that constitutively active BRK enhances proliferation and migration of 
stable MDA-MB-231 cells, we therefore considered whether BRK activation could cause an 
anchorage-independent growth advantage in soft agar in our MDA-MB-231 stable cell model 
(Figure 4.6). Notably, we observed that the ability of BRK-YF stable MDA-MB-231 cells to 
form colonies was five times greater than the parental MD-MB-231 (Figure 4.6A and B), 
indicating the importance of BRK activation in malignant transformation, hence tumorigenesis.  
We corroborated these findings in in vivo studies using an athymic mouse model system. 
The mammary fat pads of these mice (n=4 mice per group) were injected with MDA-MB-231 
cells stably expressing only one of the following genes: GFP alone, GFP-BRK-WT or GFP-
BRK-YF. The mice were monitored for tumor formation and tumor volume measured every 7 
days for 60 days (Figure 4.7A and B). All mice started developing palpable tumors 10 days after 
injection, and there was no significant difference in the latency period. However, in mice 
injected with GFP-BRK-YF-expressing cells, we observed a significantly faster growth rate 
compared to animals injected with the control cells (GFP alone) or the wild-type BRK (GFP-
BRK-WT). 60 days post- injection, the average volume of tumors induced by GFP-BRK-YF-
expressing cells was 2450 mm
3
 compared to 1130 mm
3
 for BRK-WT and 958 mm
3
 for the 
control (GFP alone) group (Figure 4.7B). Primary tumors were excised at necropsy and weighed, 
then the tumor weights were compared across the groups (Figure 4.7C). In line with the final 
tumor volume data, we observed a significantly higher average weight of the BRK-YF-
expressing tumors (3.25 gm) as compared to either BRK-WT (1.04 gm) or the control (0.81 gm) 
(Figure 4.7D). These results demonstrate that the activation of BRK significantly enhances 
tumorigenicity and suggest that the enzymatic activity of BRK is essential in BRK-regulated 
breast cancer tumor progression. 
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Figure 4.6. BRK activation promotes anchorage-independent growth of breast cancer cells. (A) 
Representative images of colony formation assay of MDA-MB-231 cells stably expressing 
control GFP or GFP-BRK-YF. 1 x 105 cells were suspended in soft agar and photographed after 
3-week incubation at 37 
o
C. (B) Cell colonies were counted in triplicate wells from five fields 
and mean of colonies were graphically represented. Standard deviations are indicated. Statistical 
analysis *p ≤ 0.05. 
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Figure 4.7. Overexpression of constitutively active BRK significantly enhanced xenograft tumor 
growth as compared with wild-type or control vector. (A) 2.5 × 10
6
 MDA-MB-231 cells were 
injected subcutaneously bilaterally into mammary fat pads of 4 animals injected per cell line. 
Palpable tumors were monitored and measured bi-weekly for about eight weeks. Tumor volume 
was calculated as follows 0.50 × length × width 
2
. (B) The average volume of tumors induced by 
GFP-BRK-YF-expressing cells was 2450 mm
3
 compared to 1130 mm
3
 for BRK-WT and 958 
mm
3
 for the control (GFP alone) group. (C) A representative image of mice at endpoint showing 
the presence or absence of tumors at the site of injection in mammary. (D) The tumors of these 
mice at endpoint were isolated and weighed and the weights represented graphically. Statistical 
analysis **P ≤ 0.001. 
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4.1.1.5. Summary  
  The activity of BRK, like Src family tyrosine kinase, is regulated negatively by 
phosphorylation of C-terminal tyrosine 447. It was previously shown that BRK-Y447F is a 
constitutively active variant because autoinhibition is disabled by the mutation of Y447. Overall 
the present study demonstrates that overexpression of constitutively active BRK highly 
correlates with increased cell proliferation and a greater transformation potential of epithelial 
cells. We demonstrated for the first time that full activation of BRK is an essential component in 
BRK-induced promotion of tumorigenesis. Using stable breast cancer cell MDA-MB-231 we 
observed significantly enhanced rates of cell proliferation, migration and transformation in BRK-
Y447F stable cells compared to wild-type stable cell lines. Our results indicate full activation of 
BRK is an essential component in the tumorigenic role of BRK. 
 
4.2. BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to 
promote cell proliferation and migration. 
 The cellular roles of BRK in breast cancer have not been fully elucidated. We found that 
constitutive activation of BRK induces anchorage-independent growth and promotes 
tumorigenesis. Although no specific BRK signaling pathway has been delineated, BRK is 
implicated in several signaling cascades. Consistent with its potential role in tumorigenesis, BRK 
associates with EGFR, enhancing the mitogenic signals by promoting the recruitment of 
phosphatidylinositol 3-kinase (PI3K) and activating Akt as well as stimulating cell migration by 
activating signalling molecules such as Mitogen-activated protein kinase (MAPK) and paxillin 
(Chen et al., 2004; Kamalati et al., 2000; Kamalati et al., 1996; Shen et al., 2008). 
More recently, it was demonstrated that depletion of BRK in breast cancer cells impairs 
the activation of EGFR-regulated signaling molecules (Ludyga et al., 2011). Data from our 
group showed significantly increased ERK activity, cell proliferation and migration in breast 
cancer cells stably expressing BRK-Y447F, and decreased migration in breast cancer cells 
depleted of BRK (Miah et al., 2012). These findings as a whole strongly suggest a role for BRK 
in promoting cell proliferation and migration.  
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The identification and characterization of an expanding repertoire of BRK interacting proteins 
and substrates has significantly improved our understanding of the molecular and cellular 
functions of BRK. A recent proteomic study reported that downstream of tyrosine kinase 1 
(Dok1), a tumor suppressor, is a potential substrate of BRK (Takeda et al., 2010). Therefore, to 
further understand the cellular roles of BRK, we explored the functional link between BRK and 
Dok1. Dok1 is a scaffolding protein which mediates protein-protein interactions and has been 
shown to be phosphorylated by several tyrosine kinases including SRMS, v-Src, c-Abl and p210-
Bcr-Abl (Goel et al., 2013; Liang et al., 2002; Mashima et al., 2009; Murakami et al., 2002; Niu 
et al., 2006; Woodring et al., 2004).  Herein we show that BRK interacts with and 
phosphorylates Dok1 predominantly on Y362, promoting its proteasome-mediated degradation. 
 
4.2.1. Results 
4.2.1.1. Dok1 is a substrate of BRK.  
In a recent report, it was suggested that Dok1 is a potential substrate of BRK (Takeda et 
al., 2010). Therefore, we investigated whether Dok1 is an endogenous target of BRK. In the 
present study, we used a mutant BRK-Y447F that was previously reported to have a higher 
enzymatic activity than BRK-WT or BRK-K219M (Lukong et al., 2005). HEK 293 cells were 
transiently transfected with GFP-Dok1 in the presence or absence of constitutively active myc-
tagged BRK (BRK-Y447F or BRK-YF). As a positive control, we used GFP-Sam68, a 
characterized substrate of BRK (Lukong et al., 2005). By immunoblotting with an anti-
phosphotyrosine antibody pY20, we showed that BRK-YF triggered strong tyrosine 
phosphorylation of GFP-Dok1, (Figure 5.1A, lane 5). Likewise, GFP-Sam68, which migrates at 
a slower rate than GFP-Dok1, was also phosphorylated as expected (lane 6). The expression 
levels of GFP-Dok1 and GFP-Sam68 as well as those of myc-BRK-YF are shown in the bottom 
panels. These data show that overexpression of constitutively active BRK induces the 
phosphorylation of ectopically expressed GFP-Dok1.  
We then examined whether ectopically expressed BRK could phosphorylate endogenous 
Dok1. To this end, we transiently transfected either the kinase-dead BRK-K219M, BRK wild 
type (BRK-WT) or the constitutively active BRK-YF into HEK293 cells followed by 
immunoprecipitation and immunoblotting (Figure 5.1B). Using a phosphotyrosine antibody, we  
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Figure 5.1. Dok1 is a direct substrate of BRK. (A) HEK293 cells were transiently transfected 
with empty control vector (-) or GFP-Dok1, GFP-Sam68, Myc-BRK or co-transfected with Myc-
BRK+GFP-Sam68 and Myc-BRK+GFP-Dok1. Tyrosine phosphorylation of cellular proteins 
were detected in total cell lysates by immunoblot analysis (IB) with an anti-phosphotyrosine 
(anti-pTyr) antibody (pY20). The blots were reprobed with anti-GFP, anti-BRK and anti-β-
tubulin antibodies as a loading control. (B) Tyrosine phosphorylated endogenous Dok1 as 
confirmed by anti-Dok1 immunoprecipitation (IP) followed by immunoblot analysis with anti-
phosphotyrosine antibody and anti-Dok1 (top panel). Immunoblot analysis of total cell lysates is 
showing the expression of Dok1, the kinase activity of BRK-WT and BRK-YF, and β-tubulin as 
a loading control (bottom panel). (C) An in vitro kinase assay was performed using the active 
kinase, GST-BRK, and the substrate, GST-C-terminus Dok1, in the presence (+) or absence (-) 
of ATP. Tyrosine phosphorylation was detected using the anti-phosphotyrosine antibody. The 
blots were reprobed with an anti-BRK and anti-Dok1 antibody (bottom panel). 
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confirmed the phosphorylation of endogenous Dok1 in Dok1 immunoprecipitates from BRK-WT 
and BRK-YF cell lysates (Figure 5.1B, top panel, lanes 3 and 4). Strikingly, we observed a 
marked decrease in the levels of phosphorylation of the Dok1 protein in the immunoprecipitates 
from the BRKY447F-transfected cell lysates. No phosphorylation of Dok1 was detected in 
control cell lysates or lysates from BRK-KM-transfected cells (lanes 1 and 2, bottom), 
suggesting that BRK may directly phosphorylate Dok1 in vivo. The expression levels of Dok1 
and activity of the transfected BRK variants (BRK-WT and BRK-YF) in the total cell lysates 
revealed strong phosphotyrosine staining as compared to either BRK-KM samples or the control 
lysates, as expected (Figure 5.1B, bottom). In light of these findings, we evaluated whether Dok1 
was a direct substrate of BRK. In an in vitro kinase assay that was performed using glutathione  
S-transferase (GST)-tagged full-length BRK and the C-terminal region of Dok1 (GST-Dok1-
CT)-terminal, we observed phosphorylation of GST-Dok1-CT in the presence of GST-BRK, 
indicating that Dok1 is a direct substrate of BRK (Figure 5.1C, lane 3, top panel). The activity of 
GST-BRK is shown by the presence of autophosphorylation (lanes 2 and 3). Together, these 
findings validate Dok1 as a bona fide BRK substrate. 
 
4.2.1.2. BRK phosphorylates Dok1 at tyrosine 362.  
Dok1 is structurally composed of an N-terminal Pleckstrin Homology (PH) domain and 
an Insulin Receptor Substrate (IRS) Type PTB domain with a C-terminal segment rich in proline 
residues and several tyrosine residues (Carpino et al., 1997) (Figure 5.2A). To map the 
tyrosine(s) on Dok1 phosphorylated by BRK, we first generated five GFP-tagged deletion 
mutants of Dok1 (Dok1-Δ1 to Δ5) (Figure 5.2A). We transfected the plasmids containing the 
Dok1 deletion mutants in the presence or absence of BRK-YF into HEK293 cells and then 
immunoprecipitated the Dok1 variants using anti-GFP antibodies. The immunoprecipitates were 
then analyzed by immunoblotting using anti-phosphotyrosine antibodies (pY20) (Figure 5.2B). 
We observed that the presence of BRK-YF induced the phosphorylation of all GFP-Dok1 
variants, except for the Dok-Δ1 and Dok-Δ2 fragments, which harbor respectively Y146 or Y146 
together with Y296 and Y315 (Figure 5.2B). Analysis of total cell lysates also corroborated the 
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phosphorylation of the Dok1 mutants (Figure 5.2C). These data confirmed that BRK targets the 
tyrosine residues in the C-terminal of Dok1.  
In order to determine which of the specific tyrosine residues along the C-terminal tail of 
Dok1 are targeted by BRK, we generated a series of 6 (Dok1-Δ1 to Δ5) GFP-Dok1 mutants in 
which one of the following tyrosine residues, Y146, Y296, Y315, Y362, Y398 or Y449 was 
replaced by a phenylalanine (Figure 5.2A). Each construct was transiently transfected into 
HEK293 cells that stably expressed the BRK-YF mutant. The Dok1 mutants were then 
immunoprecipitated from the cell lysates with anti-GFP antibodies and analyzed by  
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Figure 5.2. Constitutively active BRK phosphorylates Dok1 at Y362. (A) Schematic diagram 
of Dok1 showing different deletion and point mutants. (B) The Dok1 deletion mutants and BRK-
YF were co-transfected into HEK 293 cells, the cell were then subjected to immunoprecipitation 
with anti-GFP antibody followed by immunoblotting analysis using anti-phosphotyrosine and 
anti-GFP antibodies (top panel). The lower panel shows the expression of different GFP-Dok1 
deletion mutants, BRK (as input) and β-tubulin as a loading control. (C) Dok1 deletion mutants 
were transfected either alone or with BRK-YF into HEK293 cells, the cell lysates were then 
subjected to immunoblotting analysis using antibodies against Dok1, phosphotyrosines, BRK 
and β-tubulin as a loading control. (D) HEK293 cells were co-transfected with Dok1 point 
mutants and BRK-YF followed by immunoprecipitation with anti-Dok1 antibody and 
immunoblotting analysis using anti-phosphotyrosines and anti-Dok1 antibodies. Lower panel 
shows the expression of BRK, GFP-Dok1 mutants (as input) and β-tubulin as a loading control. 
(E) HEK293 cells were cotransfected with BRK-YF and Dok1 point mutants or transfected with 
BRK-YF alone. Total cell lysates were analyzed by immunoblotting analysis with antibodies 
against phosphotyrosines, BRK, Dok1 and β-tubulin as a loading control.  
 
 
immunoblotting using pY20. As shown in Figure 5.2D, immunoblotting with the anti-
phosphotyrosine antibodies revealed a robust phosphorylation of Dok1 wild type and all its 
mutants, except for GFP-Dok1 Y362F. The expression levels of phosphotyrosines, GFP Dok1 
mutants and BRK-YF in the total cell lysates are shown in Figure 5.2E. As a whole, although 
transient co-transfection experiments showed a weak phosphorylation of GFP-Dok1 Y362F, our 
data support the notion that BRK induces the phosphorylation of Dok1 predominantly through 
tyrosine 362.  
 
4.2.1.3. BRK interacts with Dok1 via SH3 and SH2 binding.  
BRK possesses three functional domains:  SH3, SH2, and a catalytic domain. The SH3 
domain binds to proline-rich regions typically with the PXXP motif, while the SH2 domain tends 
to bind to phosphorylated tyrosine residues. Previous studies have shown that the SH3 domain of 
BRK plays a pivotal role in substrate recognition and that the SH2 domain interacts with 
phosphorylated residues of BRK substrates. The C-terminus of Dok1 contains several proline 
residues and the entire polypeptide contains eight PXXP motifs. We, therefore, examined 
whether Dok1 interacts with BRK and whether this interaction is SH3- and/or SH2-dependent 
and direct. First we transfected GFP-Dok1 in the presence or absence of either BRK-WT or 
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BRK-YF in HEK293 cells and subjected the cell lysates to immunoprecipitation with antibodies 
against Dok1 and BRK. We found that BRK associated with Dok1 and the strongest association  
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Figure 5.3. BRK interacts with Dok1 through the SH3 domain in vivo and in vitro. (A) 
HEK293 cells were transfected with empty vector, Myc-BRK-WT, Myc-BRK-YF, GFP-Dok1 or 
co-transfected with Myc-BRK-WT/GFP-Dok1 or  Myc-BRK-YF/GFP-Dok1 and subjected to 
immunoprecipitation with anti-Dok1 and immunoblotted with BRK and Dok1 (top 2 panels). 
The expression of cellular proteins was determined in total cell lysates by immunoblotting for 
GFP, BRK and β-tubulin as a loading control. (B) BRK was immunoprecipitated with anti-BRK 
and subjected to immunoblotting analysis with anti-phosphotyrosines, anti-Dok1 and anti-BRK 
antibodies (top panels). Total cell lysates indicate the expression of BRK and Dok1 proteins. (C 
&D) HEK 293 cells were transfected with GFP-Dok1 alone or cotransfected with the indicated 
mutants of BRK and subjected to immunoprecipitation with anti-Dok1 followed by 
immunoblotting analysis with anti-BRK and anti-Dok1 antibodies.  The cellular proteins were 
determined from the total cell lysates by immunoblotting analysis with anti-BRK and anti-Dok1 
antibodies. (E) Overexpressed GFP-Dok1 or GFP-Dok1-Y362F in HEK 293 cell lysates from 
GFP-Dok1 or GFP-Dok1-Y362F expressing cells were subjected to pull-down assays with GST 
alone or recombinant GST-SH3 or GST-SH2 domain of BRK and immunoblotting analysis was 
performed with an anti-Dok1 antibody. (F) GFP-Dok1/BRK-YF or GFP-Dok1-Y362F/BRK-YF 
co-transfected cohorts of HEK 293 cell lysates were subjected to pull-down assays with GST 
alone or GST-SH3 or GST-SH2 domain of BRK   followed by immunoblotting with an anti-
Dok1 antibody. (G) Bacterially expressed GST, GST-SH3 and GST-SH2 domain of BRK 
proteins were detected via Coomassie blue staining. 
 
 
was observed in GFP-Dok1/BRK-YF samples (Figure 5.3A, lane 6). We also observed a 
reciprocal association of GFP-Dok1 in anti-BRK immunoprecipitates (Figure 5.3B). Our data 
suggest that both BRK and GFP-Dok1 interact.  
Next, to map the binding domain of BRK, we co-expressed the BRK-WT, constitutively 
active BRK-YF and kinase-inactive BRK-Y342A, as well as BRK mutants lacking an SH2 
domain (ΔSH2-BRK) or an SH3 domain (ΔSH3-BRK) with GFP-Dok1 in 293 cells. We found 
that GFP-Dok1 co-precipitated with BRK-WT, ΔSH2-BRK, BRK-Y342A and BRK-Y447F, but 
not with ΔSH3-BRK (Figure 5.3C). Analysis of the total cell lysates are shown in Figure 5.3D. 
Together, these results suggest that recognition of GFP-Dok1 was mediated primarily by SH3 
domain interactions. Interestingly, BRK-Y447F displayed a marked increase in GFP-Dok1 
binding (Figure 5.3A, B and C, lane 6).  
In order to further confirm that the binding of Dok1 to BRK was governed by the SH3 
domain and to demonstrate whether the SH2 domain preferentially binds to tyrosine 
phosphorylated Dok1, we performed glutathione S-transferase (GST) pulldown assays on cell 
lysates from HEK 293 cells transfected with GFP-Dok1 WT or GFP-Dok1Y362F alone or co-
transfected with BRKY447F. Probing with an antibody against Dok1 revealed that in the absence 
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of BRK Y447F, GFP-Dok1 WT and GFP-Dok1Y362F were able to interact with GST-BRK-
SH3, but not with the GST-BRK-SH2 (Figure 5.3E). In the presence of BRK Y447F, in addition 
to SH3-binding, we also observed a strong interaction between GFP-Dok1 WT and BRK-SH2 
domain (Figure 5.3F). However, the interaction between GFP-Dok1Y362F and BRK SH2 
domain was markedly weaker than that of GFP-Dok1 WT (Figure 5.3F, right panel). This was 
predictable since we had showed in Figure 5.2D that BRK preferentially phosphorylates Dok1 on 
Y362. These data validate that BRK interacts with Dok1 through SH3 interactions and also 
suggest that the SH2 domain of BRK interacts predominantly with tyrosine-phosphorylated 
Dok1. Taken together, our data demonstrated the interaction between Dok1 and BRK under in 
vivo and in vitro conditions occurs via SH3 and also via SH2 binding on phosphorylated Y362 of 
Dok1. 
 
4.2.1.4. Inverse correlation between the levels of BRK and Dok1 in breast cancer cells  
Since Dok1 has been described as a candidate tumor suppressor (Mashima et al., 2009; 
Mercier et al., 2011) and my data have shown that BRK has oncogenic properties (Brauer and 
Tyner, 2010; Miah et al., 2012), we opted to investigate the functional link between BRK and 
Dok1. We began by evaluating the expression of Dok1 in breast cancer cells in order to 
determine if there was any correlation between the expression profiles of both proteins. Using 
immunoblotting analysis, we examined the expression of Dok1 and BRK in nine breast cancer 
cell lines and in an immortalized mammary epithelial cell line, MCF10A, as well as in the 
HEK293 cells. All the cell lines expressed detectable levels of Dok1, except for MCF10A, 
AU565 and T47D. The strongest expression was observed in BT20 cells while weaker 
expression levels occurred in SKBRK3 and MCF7 (Figure 5.4A). BRK, on the other hand, was 
readily detectable in the breast cancer cell lines AU565, SKBR3, T47D, MCF7 and BT20, but 
not detectable in MCF10A, MDA-MB-231, MDA-MB-435, MDA-MB-468 and HBL100 (Figure 
5.4A). The localization of BRK is predominantly cytoplasmic (Lukong et al., 2005) and previous 
reports have shown that endogenous Dok1 was localized predominantly in the cytoplasm and 
plasma membrane (Niu et al., 2006; Zhao et al., 2001). Using sub-cellular fractionation studies, 
on Dok1 and BRK-positive breast cancer cell lines, SKBR3 and BT20, we found that both BRK 
and Dok1  
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Figure 5.4. BRK and Dok1 are differentially overexpressed in the human breast cancer cell 
lines. (A) Cellular proteins were detected in total cell lysates by immunoblotting analysis with 
anti-Dok1 and anti-BRK antibodies. β-tubulin expression served as a loading control. (B & C) 
SKBR3 and BT20 cells were fractionated into the cytosolic, membrane, nuclear and cytoskeleton 
fractions and subjected to immunoblotting analysis for the detection of BRK and Dok1. β-tubulin 
and Sam68 were used as controls for the cytosolic/membrane and nuclear compartments, 
respectively. (D) Stable BRK knockdown was performed on parental breast cancer cell lines 
SKBR3 using shRNA lentiviral vector plasmids against BRK and analyzed as indicated. 
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fractionated to the cytosolic and membrane fractions (Figure 5.4B and 5.4C). Since BRK and 
Dok1 were collected in the same cellular compartments and the expression levels of both 
proteins are inversely correlated, we investigated whether suppression of BRK expression by 
RNA interference could modulate the expression levels of Dok1 protein. As shown in Figure 
5.4D, using short hairpin RNA (shRNA) against BRK in SKBR3 cells, we achieved a 60-70% 
knockdown of BRK; but the suppression of BRK did not have any significant effect on Dok1 re-
expression.  
Previously it has been shown that BRK is activated following EGF stimulation (Lukong 
et al., 2005). We, therefore, investigated the effect of EGF stimulation on DOK1 expression in 
 
Figure 5.5:  The knock down of BRK in SKBR3 cells enhance DOK1 protein level. (A) 
SKBR3 cells were treated with EGF (100 ng/mL) for 0, 5, 10, 15 and 30 min and then subjected 
to immunoblot analysis for the detection of phosphotyrosines and β-tubulin (as a loading 
control). (B and C) SKBR3 and stable BRK knock down SKBR3 cells were treated with or 
without EGF (100 ng/mL) for 15 min. Total cellular proteins were determined from the cell 
lysates by performing immunoblot analysis with anti-BRK and anti-DOK1 antibodies.  β-actin 
served as a loading controls and the DOK1 expression was quantified and shown in a bar 
diagram. 
 
the presence or absence of BRK (Figure 5.5). We stimulated SKBR3 breast cancer cell lines with 
EGF and observed peak activation of EGFR signalling at 15 min. We repeated the stimulation in 
BRK-positive as well as BRK negative (knockdown) SKBR3 cells and observed that while 
treatment with EGF suppressed endogenous Dok1 expression, a detectable increase in Dok1 
levels was observed in BRK-knockdown cells (Figure 5.5B and C). Our data together indicate an 
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inverse correlation between the expression of Dok1 and BRK that is partly regulated through 
EGF stimulation.  
 
4.2.1.5. Activated BRK downregulates Dok1 protein expression  
 The inverse correlation between BRK and Dok1 prompted us to further investigate whether 
BRK activation and overexpression could modulate the expression of Dok1 protein. In addition, 
previous studies have shown that oncogenic tyrosine kinases such as p210bcr-abl and v-Src 
downregulate Dok-1 in a kinase activity-dependent manner (Niu et al., 2006). Since we recently 
reported that constitutively active BRK (BRK-Y447F) promotes tumor formation (Miah et al., 
2012), we examined whether BRK-Y447F, like oncogenic Src, could downregulate endogenous 
Dok1. We used HEK293 cells as a model to study the interaction between BRK and Dok1 since 
HEK293 cells express high levels of Dok1, but express no endogenous BRK (Figure 5.4A). We 
generated three HEK293 cell lines stably expressing GFP (empty control vector), GFP-BRK WT 
or GFP-BRK-YF by retroviral transduction. All stable cell lines expressed the transgene as 
determined by immunoblotting with the anti-GFP antibody (Figure 5.6A). Immunoblotting with 
anti-BRK confirmed the expression of GFP-BRK WT and Y447F and also validated the absence 
of BRK in HEK293 cells. The BRK-transduced cells displayed elevated levels of 
phosphorylation of cellular targets, as visualized with an anti-phosphotyrosine antibody, pY20. 
Furthermore, as expected BRK-Y447F-transduced cells displayed level of Try phosphorylation 
that were significantly higher than those of BRK-WT (Figure 5.6A). We therefore evaluated the 
expression of Dok1 in all transduced cell lines and the parental control cell line and observed a 
significant reduction in the levels of Dok1 protein in the cells transduced with constitutively 
active BRK- Y447F compared to those in the BRK-WT, GFP alone, and in the parental cells 
(Figure 5.6A, bottom panels). Since Dok1 is a tumor suppressor and we observed a dramatic 
difference between the effects of BRK-WT and BRK-Y447F on Dok1 expression, we evaluated 
the growth rates of the stable cell lines. We found that the BRK-Y447F-transduced cells 
displayed significantly higher growth rates than the cells transduced with either BRK-WT or 
GFP alone (Figure 5.6B). Taken together, our data indicate that the catalytic activation of BRK is 
critical for its ability to downregulate endogenous Dok1 and that the observed suppression of 
Dok1 may contribute to BRK-promoted cell proliferation. 
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Figure 5.6. Constitutively active BRK downregulates Dok1 protein expression. (A) 
Immunoblotting analysis of total cell lysates from HEK-293 stable cell lines is showing the 
expression of GFP alone, GFP-BRK-WT and GFP-BRK-YF (top panel), BRK (middle panel) 
and phosphorylated tyrosines (bottom panel). β-tubulin served as a loading control. The bottom 
part shows the immunoblotting analysis of endogenous Dok1 in the stable HEK293 sublines. 
Expression of Dok1 was examined by immunoblotting analysis. (B) Characterization of cell 
proliferation in response to BRK-WT and BRK-YF. The P-values were determined for control 
and stably transfected cells and set at ***P ≤ 0.0001, **P ≤ 0.001 and *P ≤ 0.05 for statistical 
significance. 
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4.2.1.5. Constitutively activated BRK diminishes the stability of Dok1 protein 
Since BRK induces the downregulation of Dok1, we then investigated the mechanisms of 
action of BRK in the downregulation of Dok1. Dok1 is a tumor suppressor and there are several 
potential mechanisms that account for the inactivation of tumor suppressors in cancer including 
those pertaining to the regulation of gene expression and post-translational events targeting 
protein stability (Herman and Baylin, 2003; Oliveira et al., 2005; Rodriguez-Paredes and 
Esteller, 2011; Yuan et al., 2001). To identify the underlying mechanisms by which BRK-Y447F 
downregulates Dok1, we first evaluated the expression of Dok1 transcripts in BRK-transduced 
HEK293 cells by both semi-quantitative RT-PCR and quantitative real-time qRT-PCR using 
Dok1-specific primers. As shown in Figure 5.7A and 5.7 B, RT-PCR and qRT-PCR analyses 
revealed no significant difference between the levels of Dok1 mRNA levels in BRK-Y447F-
transduced cells compared with cells stably expressing BRK-WT or the control cell lines. These 
results clearly indicate that BRK does not influence Dok1 mRNA levels, implying that BRK 
downregulates Dok-1 protein. 
Our results in Figure 5.7 led us to the hypothesis that BRK downregulates Dok1 by 
reducing the stability of Dok1 protein. To investigate this possibility, we examined the relative 
half-life of endogenous Dok1 protein in the presence or absence of BRK-Y447F. To this end, we 
treated various BRK-Y447F-transduced HEK293 cells and control cells at various time points 
between 1 and 24 h with cycloheximide (CHX, an inhibitor of protein synthesis). The cells were 
harvested periodically as indicated in Figure 5.8A. Western blotting of BRK-Y447F cell lysates 
showed that Dok1 protein levels were reduced by more than 50%, 75% and 95% at 8, 12 and 24 
h, respectively following treatment with CHX (Figure 5.8A, left panel). However, in the control 
samples (Figure 5.8A, right panel) the initial Dok1 protein level was reduced to half after 12 h of 
treatment with CHX and a residual level of about 25% after 24 h (Figure 5.8A, right panel). 
Statistical quantification of the levels of expression of Dok1 is provided in Figure 5.8A, lower 
panels. Our data thus indicate that Dok1 exhibited a relatively shorter half-life in cells transduced 
with BRK-Y447F compared with the control cells. These data indicate that Dok1 is a relatively 
stable protein with a physiological half-life of about 12 h and that the stability of the Dok1 
protein is compromised in the presence of constitutively active BRK. 
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Figure 5.7. Constitutively active BRK does not affect the levels of Dok1 mRNA. (A & B) 
Total RNA was isolated from HEK293 cells stably transduced with empty vector, GFP, GFP-
BRK-WT and GFP-BRK-YF. Levels of Dok1 mRNA were then analyzed using RT-PCR (A) 
and qPCR (B). RPL13A gene was used as internal control.  Error bars are the mean ± SEM of 
three biological repeats each having three technical repeats. 
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4.2.1.6. BRK downregulates Dok1 via proteasomal degradation  
We next explored the possibility that the BRK-induced downregulation of Dok1 is 
mediated by the ubiquitin-proteasome pathway (UPP). UPP plays a well-characterized key role 
in protein stability by eliminating most of the intracellular proteins in eukaryotes via degradation 
(Kerscher et al., 2006). To investigate whether Dok1 is regulated by BRK-Y447F via UPP 
associated degradation, we first examined Dok1 protein levels in the presence or absence of the 
peptide aldehyde proteasome inhibitor MG132 (carbobenzoxyl-L-leucyl-L-leucyl-L-leucine). 
MG132 is a specific proteasome inhibitor that binds reversibly to the N-terminal Thr residue of 
the β1 subunit within the 26S proteasome (Myung et al., 2001). We used the oncogenic v-Src as 
a positive control in these experiments since its effect on Dok1 stability in the presence of 
MG132 has been characterized (Janas and Van Aelst, 2011). First we examined the effect of 
MG132 on Dok1 stability in the control HEK 293 cells transduced with the empty vector. The 
cells were treated with or without MG132 for 6 or 8 h. Similar treatment with dimethyl sulfoxide 
(DMSO) served as a negative control (Figure 5.8B). We observed that MG132 treatment led to 
an increase in Dok1 protein levels in HEK293 cells (Figure 5.8B, lanes 4 and 5). The increase in 
Dok1 levels as a result of MG132 treatment indicates that the UPP associated degradation is 
indeed involved in regulating Dok1 protein turnover. We then transfected HEK 293 cells with 
plasmids expressing either BRK-Y447F or v-Src, and then treated the cells with MG132 or 
DMSO at the indicated intervals (Figure 5.8B and C). We observed a strong increase in the 
levels of the Dok1 protein following MG132 treatment in cells transfected with either BRK-
Y447F or v-Src (Figure 5.8B and C). The presence of MG132 did not affect the activity of BRK-
Y447F as indicated by comparable anti-phosphotyrosine staining (Figure 5.8B, lanes 6, 7 and 8). 
Surprising, the levels of tyrosine phosphorylation in v-Src-transfected cells were slightly lowered 
in the presence of MG132 (Figure 5.8C, lanes 6, 7 and 8). These findings suggest that the 
increase in Dok1 protein levels was the result of an inhibition of the proteasomal proteases by 
MG132. To corroborate these findings, we treated BRK-Y447F and v-Src-transfected cells for 8 
h with lactacystin, a proteasome inhibitor that binds covalently to the 26S proteasome (Fenteany 
et al., 1995). Immunoblot analysis revealed that treatment with lactacystin, akin to MG132, 
resulted in the stabilization of Dok1 protein in both BRK-Y447F and v-Src transfected cells 
(Figure 5.8D  
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Figure 5.8. Activated BRK downregulates Dok1 by reducing its stability. (A) HEK293 cells 
or HEK293-BRK-YF stable cell line were treated with a protein synthesis inhibitor 
cycloheximide (CHX: 200 µg/mL) for the indicated time points and then the cells were lysed and 
analyzed by immunoblotting for Dok1, BRK and β-tubulin as a loading control. (B) HEK293 
cells were stably transduced with HEK293-BRK-YF and treated with either a proteasome 
inhibitor MG132 (10 µM) or the vehicle DMSO as the control, at different time points (above the 
plot). Cellular proteins were determined in total cell lysates by immunoblotting analysis with 
anti-Dok1, anti-BRK, anti-phosphotyrosines antibodies. β-tubulin was used as a loading control. 
(C) Empty vector or v-Src was transiently transfected into HEK293 cells and the cells treated 
with a proteasome inhibitor MG132 (10 µM) and vehicle control DMSO for the indicated time 
points. Immunoblotting analysis of total cell lysates was performed to detect Dok1, v-Src, 
phosphotyrosines and β-tubulin served as a loading control. (D & E) HEK293 cells were 
transfected with empty control vector or BRK-YF or v-Src and treated with MG132 (10 µM), 
Lactacystin (5 µM) or control vehicle for 8 h. Then the cell lysates were subjected to 
immunoblot analysis with anti-Dok1 antibody. β-tubulin is as a loading control. (F) HEK293-
BRK-YF stable cells were transiently co-transfected with Dok1 and HA-Ubiquitin plasmids and 
after 12 h the cells were treated MG132 (10 µM) for an additional 8 h. The total cell lysates were 
subjected to immunoprecipitation with anti-Dok1 followed by immunoblotting analysis with 
anti-HA and anti-Dok1 antibodies. The inputs were analyzed as indicated. 
 
and E). These findings support our notion that both BRK and v-Src render Dok1 unstable and 
increasingly prone to degradation via the UPP. 
Finally, we examined whether the ubiquitination machinery directly mediates the BRK-
induced downregulation of Dok1. Plasmids expressing GFP-Dok1, myc-BRK-Y447F and HA-
ubiquitin were transfected into HEK293 cells. The cells were then treated with either the 
protease inhibitor, MG132 or DMSO as a negative control. We performed an 
immunoprecipitation assay using anti-Dok1 antibodies followed by immunoblotting using anti-
HA antibodies. Our data showed a significantly enhanced high molecular weight smear of 
molecules conjugated to the GFP-Dok1 immunoprecipitated in the presence of MG132 (Figure 
5.8F, lanes 6 and 7) compared with the controls in BRKY44F-expressing cells (lanes 1-5). In the 
presence of BRK-Y447F, ectopic of GFP-Dok1 and HA-Ub, in the presence or absence of 
MG132, resulted in no ubiquitination of Dok1 (Figure 5.9). It is worth noting that treatment with 
MG132 in the presence of GFP-BRK-Y447F had a greater impact on endogenous Dok1 levels 
(Figure 5.8D) than the ectopically expressed GFP-Dok1 levels (Figure 5.8F); however, the 
reason for these discrepancies is not obvious to us. Our findings as a whole strongly support the 
notion that BRK destabilizes Dok1 by promoting its ubiquitination, and an eventual degradation 
via the ubiquitin-proteasome pathway. 
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Figure 5.9: Dok1 is not ubiquitinated in the absence of BRK. HEK293 cells were transiently 
co-transfected with GFP-Dok1, HA-ubiquitin and empty Myc vector and incubated in the 
presence or absence of the proteasomal inhibitor, MG132 (10 µM) for 8 h. Cell lysates were 
subjected to immunoprecipitation with anti-Dok1 antibody and immunoblotting was performed 
with antibodies against HA and Dok1 (top panel). Total cell lysates were subjected to 
immunoblotting with antibodies against Dok1, BRK and β-tubulin as a loading control. 
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 4.2.1.7. Overexpression of Dok1 suppresses BRK-induced cell proliferation and migration  
Dok1 is a tumor suppressor and several studies have concurred that the overexpression of 
Dok1 suppresses cell proliferation and migration (Mashima et al., 2009; Mercier et al., 2011; 
Niki et al., 2004; Oki et al., 2005). Ectopic expression of Dok1 has been shown to inhibit cell 
proliferation and transformation induced by oncogenic tyrosine kinases, including the 210bcr-abl 
and Src family kinases (Janas and Van Aelst, 2011; Oki et al., 2005). 
Previously, we along with others showed that BRK overexpression and activation 
enhanced cell proliferation, cell migration and tumor formation (Ie Kim and Lee, 2009; Ikeda et 
al., 2010; Lofgren et al., 2011; Lukong and Richard, 2008; Miah et al., 2012; Xiang et al., 2008). 
To test whether Dok1 can also modulate the oncogenic properties of BRK, we evaluated the 
effect of Dok1 on BRK-induced cell proliferation and migration. HEK 293 cells stably 
expressing GFP alone, GFP-BRK-WT and GFP-BRKY447F were infected with adenoviruses 
expressing mCherry-Dok1 (Figure 5.10A). In the absence of mCherry-Dok1, cells stably 
expressing GFP-BRKY447F displayed a significantly higher growth rate compared with GFP-
BRK-WT expressing cells as well as the control cell lines (Figure 5.10B). Remarkably, the 
introduction of Dok1 resulted in a dramatic decrease in the rate of growth of the BRK-Y447F-
transduced cells, similar to the levels exhibited by the control and BRK-WT cells (Figure 5.10C). 
Similar results were obtained with BRK-negative cells lines MDA-MB-231 stably expressing 
BRK variants BRK-Y447F or BRK-WT (Figure 5.11). These data indicate that the 
overexpression of Dok1 suppresses BRK-induced cell proliferation. 
Finally, we employed wound healing assays to assess the effect of Dok1 on BRK-induced 
cell migration using the same set of cell lines described in Figure 5.10B and C. The cell surfaces 
were scratched and photo-micrographs taken at different time intervals between 0 and 24 h. 
Figure 5.10D and F show representative images taken at 0 and 24 h. The results showed that the 
overexpression of BRK-Y447F accelerated the wound healing process as observed by the 
reduced size of the wounded area after 24 h compared to either the BRK-WT or control samples 
(Figure 5.10D). Furthermore, the ectopic expression of Dok1 reduced the migration rates of the 
BRK-Y447F cells to near control rates (Figure 5.10F). The results are quantified in Figure 5.10E 
and G. These results were reproduced using MDA-MB-231 cells stably expressing the BRK  
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Figure 5.10. Dok1 inhibits BRK-induced cell proliferation and migration. (A) HEK293 
stable sub-cell lines were transduced with mCherry-Dok1 using adenoviral vector. Cellular 
proteins were detected in total cell lysates by immunoblotting analysis with anti-BRK, anti-
Dok1, and anti-phosphotyrosine antibodies. β-tubulin served as a loading control. (B & C) 
HEK293 stable cells were transduced with or without mCherry-Dok1adeno-vector and were 
monitored for cell proliferation. (D & E) Cell migration determined by the healing of a fixed 
wound area induced in the different HEK293 stable cells. The percentage of open area at 24 h is 
plotted. (F & G) Cell migration analysis was performed with the indicated stable cell lines 
expressing mCherry-Dok1 or an empty vector. The assay was based on the rate of wound closure 
in the scratched cells. The percentage of open area at 24 h is plotted. The migration assay was 
performed in three independent experiments. Data were means ± standard errors. Statistics: and 
**P ≤ 0.001 and ***P ≤ 0.0001. 
 
 
 
Figure 5.11:  Dok1 inhibits BRK-induced cell proliferation in MDA-MB 231 cells. (A and B) 
MDA-MB 231 stable cells (GFP alone, GFP-BRK-WT and GFP-BRK-YF) were transduced with 
or without mCherry-Dok1adeno-vector and were monitored for cell proliferation by Coulter 
Counter. 
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Figure 5.12:  Dok1 inhibits BRK-induced cell migration in MDA-MB 231 cells. (A & B) 
MDA-MB 231 stable cells were transduced with or without mCherry-Dok1adeno-vector and 
were monitored for cell migration based on the healing of the wound area. The percentage of 
open area at 24 h is plotted. (C & D) Cell migration analysis was performed with the indicated 
stable cell lines expressing mCherry-Dok1 or an empty vector. The assay was based on the rate 
of wound closure in the scratched cells. The percentage of open area at 24 h is plotted. The 
migration assay was performed in three independent experiments. Data were means ± SD. 
Statistics: *P ≤ 0.05 and **P ≤ 0.001. 
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variants (Figure 5.12). Taken together, these data confirm the anti-oncogenic properties of Dok1 
and suggest that downregulation of Dok1 is one of the mechanisms by which BRK manifests its 
oncogenic function. 
 
4.2.1.8. Summary  
The overexpression of BRK has been shown to sensitize mammary epithelial cells to 
mitogenic signaling and to promote cell proliferation and tumor formation. The identification 
and characterization of BRK target proteins have helped in understanding of the potential 
molecular mechanisms of BRK. In this study, we demonstrate a functional link between Dok1 
depletion and the regulation of BRK-induced cellular processes such as cell proliferation and 
migration. Downstream of tyrosine kinases 1 or Dok1 is a scaffolding protein and a substrate of 
several tyrosine kinases. Herein we show that BRK interacts with and phosphorylates Dok1 
specifically on Y362. We demonstrate that this phosphorylation by BRK significantly 
downregulates Dok1 in a ubiquitin-proteasome-mediated mechanism. Together, these results 
suggest a novel mechanism of action of BRK in the promotion of tumor formation, which 
involves the targeting of tumor suppressor Dok1 for degradation through the ubiquitin-
proteasomal pathway. 
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5. Discussion 
5.1. Activation of breast tumor kinase (BRK) is essential for cell migration and tumor 
development. 
BRK is a tyrosine kinase with a functional architecture and modes of regulation 
reminiscent of Src family kinases. Like Src kinases, BRK is regulated negatively by 
phosphorylation of C-terminal tyrosine 447 and positively by phosphorylation of tyrosine 342 in 
the catalytic domain (Derry et al., 2000; Qiu and Miller, 2002). The BRK C-terminal tyrosine 
residue 447 and 342 are analogous to the human Src regulatory Y530 and Y419 respectively 
(Derry et al., 2000; Qiu and Miller, 2002). Csk phosphorylates the C-terminal tyrosine of Src 
kinases, promoting intramolecular interactions that lock the Src kinases in an inactive 
conformation (Okada and Nakagawa, 1989). Therefore, Tyr530Phe mutation or 
dephosphorylation activates Src (Hunter, 1987).  This dephosphorylation is often accompanied 
by autophosphorylation of pTyr419 within the activation loop, and results in a 10-fold increase 
in kinase activity (Boggon and Eck, 2004). Prevention of autophosphorylation by Tyr419-Phe 
mutation suppresses this activation by about 5 fold (Kmiecik and Shalloway, 1987; Piwnica-
Worms et al., 1987), demonstrating the importance of synergy in Src activation. Therefore, the 
classical activation pathway of Src includes dephosphorylation of Y530 to initiate a 
conformational change of the protein (partial activation) that promotes full activation by 
autophosphorylation of tyrosine site 419. The transmembrane receptor protein tyrosine 
phosphatase (RPTP)α has been shown to activate Src by 5-fold by dephosphorylating both 
pTyr530 and pTyr419 in vivo  (Pallen, 2003). Clinically, dephosphorylated Y530Src is 
associated with early stages of carcinogenesis in breast cancer patients (Elsberger et al., 2010). 
However, the negative and positive regulators of BRK activity have not been identified. 
In this study, in order to investigate the role of full activation of BRK on the oncogenic 
properties of BRK, we generated constitutively active mutant of BRK by mutating Tyr447 to 
Phe. We first evaluated the activities of various GFP-tagged and non-tagged BRK mutants and 
determined that in both cases certain mutant forms of BRK, including BRK-YF, displayed higher 
activity than wild-type BRK when transfected into HEK293 cells (Figure 4.1B) as has been 
previously demonstrated (Lukong et al., 2009; Qiu and Miller, 2004). We next generated three 
sets of stable cell lines overexpressing GFP-BRK-WT and fully activated GFP-BRK-Y447F, as 
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well as a GFP-alone control (Figure 4.2B). The cell lines selected for these studies included 
HEK293 cells, immortalized mammary epithelial cell line, MCF10A and highly invasive breast 
cancer cell line, MDA-MB-231. These cell lines expressed little or no BRK (Figure 4.2A). We 
observed hyperactivation in BRK-YF stable cell lines compared to BRK-WT and controls 
(Figure 4.2C). Using our stable cell lines, we present evidence that support a critical role for 
BRK activity in the promotion of the oncogenic processes such as cell proliferation and 
migration, and tumor formation in vivo. 
Mitogenic signaling involves the sequential activation of a MAPK (mitogen-activated 
protein kinase) kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and the MAPK (Krishna 
and Narang, 2008). There are four distinct MAPK signaling cascades, all of which have been 
implicated in breast cancer. They are the extracellular regulated kinase ERK 1/2 pathway, the 
ERK5 pathway, the p38 pathway and the c-Jun N-terminal kinase (JNK) pathway (Krishna and 
Narang, 2008; Wang and Tournier, 2006). ERK 1/2 is significantly activated in a large subset of 
mammary tumors (Mueller et al., 2000) and persistent activation of ErbB2 oncogene in MCF-
10A is associated with activation of ERK 1/2 (Seton-Rogers et al., 2004). Previous studies have 
demonstrated that exogenous expression of BRK enhanced EGF-induced proliferation of normal 
mammary epithelial cells EGF (Kamalati et al., 1996). We previously demonstrated that 
phosphorylation of BRK substrate Sam68 upon EGF stimulation is partly BRK-dependent 
(Lukong et al., 2005). Here we show that full activation of BRK results in significantly higher 
cell growth rates is associated with hyperactivation of ERK 1/2 (Figure 2D and E), consistent 
with a previous study (Li et al., 2012). We did not observed any effect of BRK on the activation 
of ERK5, p38 or JNK (data not shown) although Ostrander et al in their study showed that BRK 
regulates ERK5 and p38 activation albeit in heregulin-induced conditions (Ostrander et al., 
2007). 
Accumulating evidence has highlighted the importance of BRK in cell migration. For 
instance, BRK activation downstream of the EGFR resulted in increased Rac1 activity, 
associated with migration and invasion programs in both skin and breast cancer cell lines (Chen 
et al., 2004). A recent study indicated that silencing BRK in HER2-positive breast cancer cell 
lines BT20 and JIMT1 decreased HER2 activation and reduced cell migration (Ludyga et al., 
2011). In our study, using both the wound-healing and Transwell assays we showed that stable 
knockdown of BRK in both BT20 and SKBR3 cells which are HER2-positive and negative cell 
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lines respectively, cell migration was significantly reduced (Figure 4.4 and 4.5B and C). This 
implies that BRK can regulate cell migration in an EGFR-independent pathway. Similarly, stable 
expression of wild-type BRK and constitutively active BRK in HER2-negative MDA-MB-231 
significantly increased cell migration (Figure 4.3 and 4.5A). We also confirmed the transforming 
potential of the Y447F mutant by evaluating the capacity our stable cell lines for anchorage-
independent growth. Consistent with previous reports, stable expression of BRK-Y447F resulted 
in a significant increase in size of colonies formed in soft agar (Kamalati et al., 1996; Kim and 
Lee, 2005). 
Next we examined if activation of BRK was essential for tumor formation in vivo. We 
transplanted our engineered MDA-MB-231 stable cell lines into immune compromised mice and 
measured the tumor volume over time (Figure 4.7). We noted that the fully activated form of 
BRK promoted a more rapid tumor growth as compared to the wild-type BRK or the control. 
Overexpression of wild-type BRK was previously shown by Shen et al to promote tumor growth 
in animal (Shen et al., 2008), but our data stresses the importance of BRK activity in the 
promotion of tumor growth. The exact mechanism by which BRK promotes migration and 
tumorigenesis is unknown. We have shown that BRK may regulate these processes via activation 
of the Raf1-MEK1/2 ERK1/2 cascade as demonstrated by hyperphosphorylation of ERK1/2 in 
the BRK stable cell lines (Figure 4.2E). In other studies, it was suggested that BRK promotes 
cell migration and invasion through p190RhoGAP phosphorylation that results in the activation 
of Ras to promote cell migration (Shen et al., 2008).  
Overall this study demonstrates that overexpression of constitutively active BRK highly 
correlates with exaggerated cell proliferation and ultimately, with increased transformation 
potential of epithelial cells. We have, however, demonstrated for the first time that full activation 
of BRK is an essential component in the promotion of tumorigenesis by BRK in vivo. Therefore, 
it can be predicted that BRK hyperactivation in human breast cancers might exhibit an 
aggressive clinical behavior. We know from a recent study that mammary-targeted expression of 
wild-type BRK promoted infrequent mammary tumors with delayed latency (Lofgren et al., 
2011). Based on our results, the question of whether activated BRK is capable of directly 
inducing mammary gland tumors is feasible. Furthermore, many studies have reported that 
elevation of Src activity in human tumors including breast cancer correlates with disease stage 
and poor prognosis (Elsberger et al., 2010; Summy and Gallick, 2003). Hence future profiling of 
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the BRK activation in a large cohort of breast tumor samples may enable the use of BRK 
activation as a diagnostic or prognostic marker, and inhibition of BRK activity or activation as a 
viable therapeutic strategy in breast cancer treatment. 
 
5.2. BRK induces Dok1 degradation via the ubiquitin proteasomal pathway to promote cell 
proliferation 
It has recently been shown that constitutive activation of BRK promotes cell proliferation 
and migration as well as tumor formation, validating the proto-oncogenic function of BRK (Miah 
et al., 2012). However, the molecular mechanisms dictating the tumorigenic role of BRK are 
poorly understood. An increasing number of studies have reported an inhibitory function of 
oncogenic tyrosine kinases towards overcoming cellular and physiological constraints promoted 
by tumor suppressors (Blume-Jensen and Hunter, 2001; Dai et al., 1998; Fry et al., 2009; Kirisits 
et al., 2007; Peng et al., 2010). Members of the Dok1 family have been characterized as negative 
regulators of cell transformation induced by oncogenic tyrosine kinases (Mashima et al., 2009). 
In the present study, we demonstrate for the first time that BRK mediates its oncogenic function 
at least in part by downregulating the tumor suppressor Dok1. We show that: 1) BRK interacts 
and phosphorylates Dok1 predominantly at tyrosine 362; 2) the levels of BRK and Dok1 in 
breast cancer cells are inversely correlated; 3) activated BRK promotes Dok1 protein 
downregulation via ubiquitin-proteasome degradation; and 4) Dok1 is a negative regulator of 
BRK-induced cell proliferation and migration. 
The function of Dok1 is regulated upon phosphorylation by a variety of receptor and non-
receptor tyrosine kinases including the Src tyrosine kinase family members Lck and Fyn 
(Nemorin and Duplay, 2000), as well as tyrosine kinases such as Tec and Bcr-Abl (Gerard et al., 
2004; Lee et al., 2004; Liang et al., 2002; Noguchi et al., 1999; Woodring et al., 2004). It has 
also been demonstrated that Src phosphorylates Dok1 and prevents its entry into the nucleus (Niu 
et al., 2006). Recently, Takeda et al. identified Dok1 as a substrate of several tyrosine kinases 
including BRK (Takeda et al., 2010). In the present study, we provide evidence that Dok1 
interacts with and is a direct substrate of BRK. In cells stably expressing BRK, ectopically 
expressed Dok1 is phosphorylated preferentially on Y362. We noted that co-expression of BRK 
and Dok1 also resulted in the phosphorylation at other tyrosines, besides Y362, although the 
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phosphorylation signal was weak. The reasons for these discrepancies in the phosphorylation 
pattern of Dok1 by BRK were not obvious. It is tempting to speculate that at steady state levels, 
BRK is more specific in its phosphorylation of Dok1. It was previously shown that Y361, and 
Y450 of murine Dok1, equivalent to Y362, and Y449 of its human homologue, are all direct 
phosphorylation sites of Src (Niu et al., 2006; Shah and Shokat, 2002). Phosphorylation at Y362 
is not surprising since the Y361DEP motif in murine Dok1 fits the optimal consensus 
phosphorylation site for Src (Shah and Shokat, 2002). However, the LY450QSV motif is not 
optimal for Src phosphorylation, although the pYXXV motif has been shown to be an optimal 
binding site for the c-Src tyrosine kinase SH2 domain (Shah and Shokat, 2002). Like Src, it is, 
therefore, possible that BRK could also phosphorylate unpredictable sites, based on the apparent 
heterogeneity of the consensus motif. 
Dok1 was also shown to be repressed in other forms of cancer including head and neck 
cancer (HNC), lung, liver, and gastric cancers, likewise in Burkitt's lymphoma (Balassiano et al., 
2011; Lambert et al., 2011; Saulnier et al., 2012). Dok1 repression was suggested to been a 
consequence of aberrant promoter hypermethylation (Balassiano et al., 2011; Lambert et al., 
2011; Saulnier et al., 2012), although surprisingly no expression studies of Dok1 were found in 
the literature to support these findings. We evaluated the correlation between Dok1 and BRK in 
breast cancer cell lines, because of the overexpression of BRK in the majority of breast cancer 
(Brauer and Tyner, 2010; Miah et al., 2012). We observed an inverse correlation between the 
expression patterns of the two proteins, although the knockdown of BRK resulted only in a slight 
restoration of Dok1 levels in SKBR3 cells. However, it is not yet known whether the expressions 
of Dok1 and BRK in breast cancers are regulated epigenetically via promoter hypermethylation. 
Interestingly, there is evidence of BRK promoter hypomethylation in cisplatin resistant ovarian 
cancer cells (Yu et al., 2011). 
In the present study, we also show that both BRK and Dok1 are predominantly expressed 
as cytoplasmic/membrane proteins (Figure 5.4B and C) as was previously reported (Brauer and 
Tyner, 2010; Lee et al., 2004; Lukong et al., 2005; Noguchi et al., 1999).  A proportion of both 
proteins also localize in the nucleus (Lukong et al., 2005; Niu et al., 2006). We and others 
reported that BRK phosphorylates nuclear Sam68 and promotes its subcellular relocalization 
(Brauer and Tyner, 2010; Lukong et al., 2005). Dok1, on the other hand, was recently shown to 
shuttle between the nucleus and cytoplasm in a mechanism that is regulated by external stimuli 
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and Src phosphorylation (Niu et al., 2006). Further research is needed to determine whether 
BRK also regulates the subcellular localization of Dok1.  
Both p210bcr-abl and v-Src have been shown to downregulate Dok-1 in a kinase activity-
dependent manner (Niu et al., 2006). BRK was recently shown to phosphorylate Cbl, inducing 
its auto-ubiquitination and degradation through the ubiquitin-proteasome pathway (Kang and 
Lee, 2013). In the present work, we found that the constitutively active BRK also induced the 
degradation of Dok1, but had no effect on its transcript levels (Figures 5.6, 5.7 and 5.8). 
Intriguingly, in comparison to BRK-YF, BRK WT induced little to no effect on Dok1 protein 
levels.  This is reflective of a kinase-dependent mechanism by which BRK downregulates Dok1 
protein levels. This, however, raises the critical question as to how endogenous BRK is able to 
regulate Dok1 protein levels.  It was previously shown that the ability of BRK to phosphorylate 
its endogenous substrate Sam68 in breast cancer cells was significantly enhanced by stimulation 
with epidermal growth factor (EGF) (Lukong et al., 2005). Dok1 is a scaffolding protein and in 
the present study we have shown that BRK interacts with Dok1 via its SH3 domain (Figure 
5.3E). It is conceivable that EGF stimulation may lead to BRK activation followed by its 
interaction, phosphorylation and therefore destabilization/degradation of Dok1 as shown in 
figure 5.5. It may be worth noting that the activation of protein tyrosine kinases via the transient 
treatment of fibroblast cells with platelet-derived growth factor (PDGF) did not induce a 
decrease in Dok1 expression (Janas and Van Aelst, 2011). Rather this effect of BRK on Dok1 
may have been achieved through prolonged stimulation of BRK leading to its activation as 
demonstrated in the current work. It is not clear at this stage whether the effect of BRK was 
direct. We showed that tyrosine phosphorylated Dok1 interacts with the SH2 domain of BRK. 
How this interaction affects accessibility to the proteasomal machinery is not known. However, 
it is possible that activated BRK may have triggered other cellular events that culminated in 
other posttranslational modifications promoting Dok1 degradation. Usually, polyubiquitin chains 
are covalently bound to lysine residues in proteins targeted for degradation (Kerscher et al., 
2006). While we conclude that the BRK-induced degradation of Dok1 is via the ubiquitin-
proteasomal pathway, at this stage we did not provide direct evidence that this is a lysine-
dependent mechanism. Ideally, a Dok1 substrate in which all lysine residues have been mutated 
to arginines will serve as a better negative control for the study of BRK-induced ubiquitination 
of Dok1. We did not test this possibility since studies with other oncogenic tyrosine kinases have 
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observed only a modest increase in the expression levels of the lysine-less mutant (Janas and 
Van Aelst, 2011), raising the possibility that other potential posttranslational modifications might 
be involved in the ubiquitination process. 
Finally, we provided a functional link between Dok1 inactivation and the regulation of 
BRK-induced cellular processes such as cell proliferation and migration. Dok1 itself has been 
shown to inhibit mitogenic signaling and cell proliferation, and to antagonize leukemogenesis, 
but paradoxically, it also promotes cell spreading, motility, and apoptosis (Di Cristofano et al., 
2001; Hosooka et al., 2001; Niki et al., 2004; Woodring et al., 2004; Yasuda et al., 2004). 
Inhibition of Dok1 expression has been associated with enhanced cell proliferation (Mercier et 
al., 2011; Miao et al., 2003). We showed in Figure 5.10 B and C that activated BRK-induced 
proliferation of stable HEK293 cells was inhibited in the presence of overexpressed Dok1. 
Similarly, Dok1 suppressed BRK-induced migration of these cells. Taken together, our findings 
suggest that Dok1 is a negative regulator of the BRK-promoted oncogenic cellular processes, in 
particular, cell migration and proliferation. Further studies are needed to comprehensively 
elucidate the physiological implications of Dok1 and other members of the DOK gene family in 
BRK-regulated mammary tumorigenesis using for instance xenograft mouse models. 
In summary, our data show that Dok1 is phosphorylated and targeted for ubiquitin-
proteasomal degradation, a process that is critical for the sustenance of BRK-induced cell 
migration and proliferation. Further in vivo studies are required to support a model in which 
Dok1 impacts BRK-driven tumorigenesis and metastasis.  
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6. Conclusion 
BRK is a non-receptor protein tyrosine kinase and its kinase activity like Src is negatively 
regulated by a phosphorylatable regulatory C-terminal tyrosine 447. Mutation of this regulatory 
C-terminal tyrosine 447 to phenylalanine results in a constitutively active variant because BRK-
Y447F significantly enhances the catalytic activity of the enzyme. I showed that constitutive 
activation of BRK promotes cell proliferation and cell migration, validating a proto-oncogenic 
function of BRK. Additionally we also demonstrated for the first time that full activation of BRK 
is an essential component in the promotion of tumorigenesis by BRK in vivo. However, the 
molecular mechanisms dictating the tumorigenic role of BRK are poorly understood. In the 
present study, we demonstrated for the first time that BRK mediates its oncogenic function at 
least in part by downregulating the tumor suppressor Dok1. We have shown that the level of 
BRK and Dok1 in breast cancer cells are inversely correlated and BRK-induced cell proliferation 
and migration by phosphorylating Dok1 and leads its degradation via ubiquitin-proteasomal 
pathway. Further studies are needed to comprehensively elucidate the physiological implications 
of Dok1 and other members of the Dok gene family in BRK regulated mammary tumorigenesis 
using xenograft mouse models for instance. 
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7. Future directions 
 
7.1. Enzymatic activation is essential for BRK to induce mammary gland tumorigenesis 
and metastasis. 
BRK is a member of a non-receptor protein tyrosine kinase family, which is 
evolutionarily conserved across species (Goel and Lukong 2015). It has been reported that more 
than 80% of invasive ductal carcinomas highly express BRK (Harvey et al., 2013). This 
overwhelming presence of BRK in most of the mammary gland tumors implies a role for this 
non-receptor protein tyrosine kinase in the etiology of breast cancer. In fact, it is reported that 
BRK is involved in cell proliferation, differentiation, colony formation and also in tumor 
progression in vivo (Miah et al., 2013). Additionally, the chromosomal location of BRK is 
20q13.3, a region that is frequently amplified in breast cancer (Harvey and Crompton et al., 
2004). Moreover BRK contains multiple proteins interaction motifs by which it interacts with 
numerous signal transduction molecules (Goel and Lukong 2015), and regulates different signal 
transduction pathways including such as EGFR, PI3K/AKT, MAPK, MET and IGF-1R (Goel 
and Lukong 2015). 
Transgenic mouse models have helped in the understanding the possible role of BRK in 
mammary tumorigenesis. Two transgenic mouse models generated thus far expressed wild-type 
BRK in mouse mammary glands (Lofgren et al., 2011; Peng et al., 2013). In both cases the 
penetrance was very low and the latency was very long compared to those of other oncogene 
including HER2 and polyoma middle T transgenic (Goel and Lukong 2015).  
In my Ph.D. research work, I showed that constitutively active form of BRK significantly 
enhanced the cell proliferation, migration, colony formation as well as tumor formation in 
xenograft mouse model in comparison to wild type BRK indicating that the full activation of 
BRK is required for cellular transformation. In my study, I also revealed one of the molecular 
mechanisms of action of BRK by characterization of a BRK target protein Dok1. BRK 
phosphorylated tyrosine 362 of Dok1 for ubiquitin-mediated proteasomal degradation, which has 
tumor suppressor activity to promote cell proliferation, and migration, however, the oncogenic 
function of BRK can be nullified by overexpressing Dok1 in in vitro culture system. Together, 
these results suggest a novel mechanism of action of the constitutively active form of BRK in the 
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promotion of cell proliferation, migration and tumor formation by targeting Dok1 for 
degradation through the ubiquitin-proteasomal pathway. 
To date, the oncogenic function of the constitutively active form of BRK has largely been 
studied in in vitro culture system. Despite significant progress in the characterization of BRK, 
the critical physiological role of the constitutively active form of BRK (BRK-Y447F) in the 
context of mammary gland tumorigenesis has not been addressed. Targeting the constitutively 
active BRK Y447F to the mouse mammary gland could provide a better model for the study of 
the role of BRK in mammary tumorigenesis. This mouse model can be crossed with an MMTV-
Dok1 or MMTV-Dok1Y362F mice to validate that physiologically, BRK can promote Dok1 
degradation and therefore enhance tumorigenesis.  In this future study, the following question 
will be answered; A) Can constitutively active form of BRK (BRK-Y447F) potentiate mammary 
gland tumorigenesis in mice like oncogene HER2; and B) Can Dok1-Y362F expression nullify 
the BRK-Y447F induced mammary gland tumorigenesis and metastasis in mice. 
 
7.2. To determine the effect of activated form of BRK on genes regulation 
 
  Tumorigenesis is characterized by aberrant cell signaling culminating in increased cell 
proliferation, cell migration and prolonged cell survival. Likewise, in my studies I have shown 
that the aberrant activation of BRK results into the increased cell proliferation, migration and 
tumor formation. Tyrosine kinases are key regulators of various signaling cascades that control 
the transcription of various genes. It is would, therefore, be interesting to examine if the aberrant 
activation of BRK has a direct or indirect influence on transcriptional regulation of genes. In 
order to examine the effect of BRK or its activated form on gene expression profiles, we 
performed microarray studies using lysates from various cell lines stably expressing BRK WT, 
BRK-Y447F or an empty vector as a control. We observed differential gene expression profiles 
between the control and the BRK-WT or BRK-YF. CCD1, BOP1, CD44, CHCHD2 and RLP19 
were among the genes that were upregulated in the presence of BRK (WT and Y447F); whereas, 
CTNNB1 and MMP10 are examples of genes that were down-regulated (Figure 6.1.1). These 
results can be complemented with experiments using stably BRK knockdown cells to examine 
whether stably overexpressed BRK and stably knocked down BRK have opposing effects of 
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transcription. By corroborating these two sets of data, the genes regulated by BRK can be 
specified which will provide a better understanding the effect of BRK on gene regulation in 
breast cancer. In addition, it will be very helpful to further understand the mechanism of action 
of BRK and perhaps provide new ways of inhibiting the activity of BRK in BRK-positive breast 
cancer patients. 
 
 
Figure 6.1.1. Semi-quantitative RT-PCR analysis to validate the effect of BRK on the 
mRNA levels of some of the genes identified by microarray analysis. Semi-quantitative RT-
PCR was performed for the indicated differentially expressed genes with the cDNAs from HEK 
293 cells stably expressing GFP, GFP-BRK-WT and GFP-BRK-YF. The reactions were 
conducted using the ProtoScript® M-MuLV Taq RT-PCR Kit as described by the manufacturer. 
The primers for GAPDH were supplied by the manufacturer and were used for internal control 
reactions.  
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